Prestige Consumer Healthcare (PBH) 10-Q 3 Nov 16 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2016	Oct. 28, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Prestige Brands Holdings, Inc.
Entity Central Index Key	1,295,947
Current Fiscal Year End Date	--03-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		52,934,148

Consolidated Statements of Inco

Consolidated Statements of Income and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues
Net sales	$ 215,017	$ 205,262	$ 423,787	$ 396,549
Other revenues	35	803	840	1,648
Total revenues	215,052	206,065	424,627	398,197
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	91,087	86,125	179,071	166,021
Gross profit	123,965	119,940	245,556	232,176
Operating Expenses
Advertising and promotion	28,592	27,893	56,227	54,315
General and administrative	18,795	16,462	38,252	34,051
Depreciation and amortization	6,016	5,687	12,848	11,407
(Gain) loss on sales of assets	(496)	0	54,957	0
Total operating expenses	52,907	50,042	162,284	99,773
Operating income	71,058	69,898	83,272	132,403
Other (income) expense
Interest income	(46)	(33)	(103)	(60)
Interest expense	20,876	20,700	42,060	42,611
Loss on extinguishment of debt	0	0	0	451
Total other expense	20,830	20,667	41,957	43,002
Income before income taxes	50,228	49,231	41,315	89,401
Provision for income taxes	18,033	17,428	14,651	31,425
Net income	$ 32,195	$ 31,803	$ 26,664	$ 57,976
Earnings per share:
Basic (in USD per share)	$ 0.61	$ 0.60	$ 0.50	$ 1.10
Diluted (in USD per share)	$ 0.60	$ 0.60	$ 0.50	$ 1.09
Weighted average shares outstanding:
Basic (in shares)	52,993	52,803	52,941	52,676
Diluted (in shares)	53,345	53,151	53,329	53,055
Comprehensive income, net of tax:
Currency translation adjustments	$ 2,703	$ (11,079)	$ (3,121)	$ (11,484)
Total other comprehensive (loss) income	2,703	(11,079)	(3,121)	(11,484)
Comprehensive income	$ 34,898	$ 20,724	$ 23,543	$ 46,492

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Current assets
Cash and cash equivalents	$ 30,458	$ 27,230
Accounts receivable, net	92,869	95,247
Inventories	97,959	91,263
Deferred income tax assets	10,646	10,108
Prepaid expenses and other current assets	11,341	25,165
Assets held for sale	36,400	0
Total current assets	279,673	249,013
Property and equipment, net	13,732	15,540
Goodwill	351,662	360,191
Intangible assets, net	2,181,128	2,322,723
Other long-term assets	4,783	1,324
Total Assets	2,830,978	2,948,791
Current liabilities
Accounts payable	39,041	38,296
Accrued interest payable	8,264	8,664
Other accrued liabilities	67,006	59,724
Total current liabilities	114,311	106,684
Long-term debt
Principal amount	1,502,000	1,652,500
Less unamortized debt costs	(22,337)	(27,191)
Long-term debt, net	1,479,663	1,625,309
Deferred income tax liabilities	459,527	469,622
Other long-term liabilities	2,837	2,840
Total Liabilities	2,056,338	2,204,455
Commitments and Contingencies
Stockholders' Equity
Preferred stock - $0.01 par value; Authorized - 5,000 shares; Issued and outstanding - None	0	0
Common stock - $0.01 par value; Authorized - 250,000 shares; Issued - 53,265 shares at September 30, 2016 and 53,066 shares at March 31, 2016	532	530
Additional paid-in capital	453,336	445,182
Treasury stock, at cost - 331 shares at September 30, 2016 and 306 shares at March 31, 2016	(6,558)	(5,163)
Accumulated other comprehensive loss, net of tax	(26,646)	(23,525)
Retained earnings	353,976	327,312
Total Stockholders' Equity	774,640	744,336
Total Liabilities and Stockholders' Equity	$ 2,830,978	$ 2,948,791

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2016	Mar. 31, 2016
Stockholders' Equity:
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	53,265,000	53,066,000
Treasury stock, (in shares)	331,000	306,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net income	$ 26,664	$ 57,976
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	12,848	11,407
Loss (gain) on sales of intangible assets and property and equipment	55,112	(36)
Deferred income taxes	(10,602)	21,985
Amortization of debt origination costs	5,097	4,055
Stock-based compensation costs	3,933	5,034
Loss on extinguishment of debt	0	451
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable	356	(3,918)
Inventories	(10,663)	(3,838)
Prepaid expenses and other current assets	10,112	3,436
Accounts payable	820	(4,519)
Accrued liabilities	6,605	(1,443)
Net cash provided by (used in) operating activities	100,282	90,590
Investing Activities
Purchases of property and equipment	(1,404)	(1,683)
Proceeds from sales of intangible assets	52,353	0
Proceeds from the sale of property and equipment	75	344
Net cash provided by (used in) investing activities	51,024	(1,339)
Financing Activities
Term loan repayments	(130,500)	(50,000)
Borrowings under revolving credit agreement	20,000	15,000
Repayments under revolving credit agreement	(40,000)	(55,000)
Payments of debt origination costs	(9)	(4,211)
Proceeds from exercise of stock options	3,423	6,398
Proceeds from restricted stock exercises	0	544
Excess tax benefits from share-based awards	800	1,850
Fair value of shares surrendered as payment of tax withholding	(1,395)	(2,187)
Net cash used in financing activities	(147,681)	(87,606)
Effects of exchange rate changes on cash and cash equivalents	(397)	(811)
Increase in cash and cash equivalents	3,228	834
Cash and cash equivalents - beginning of period	27,230	21,318
Cash and cash equivalents - end of period	30,458	22,152
Interest paid	37,259	40,550
Income taxes paid	$ 6,743	$ 3,707

Business and Basis of Presentat

Business and Basis of Presentation	6 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	Business and Basis of Presentation Nature of Business Prestige Brands Holdings, Inc. (referred to herein as the “Company” or “we”, which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct and indirect 100% owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter (“OTC”) healthcare and household cleaning products to mass merchandisers, drug stores, supermarkets, and club, convenience, and dollar stores in North America (the United States and Canada) and in Australia and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no operations and is also the parent guarantor of the senior credit facility and the senior notes described in Note 10 to these Consolidated Financial Statements. Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2017”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and six months ended September 30, 2016 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2017 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016 . Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate. Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2016 are uninsured, and approximately 27.8% of our consolidated cash balances at September 30, 2016 are located in the United States. Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance. Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level. Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value. Debt Origination Costs We have incurred debt origination costs in connection with the issuance of our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility. Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising. Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Warehousing, shipping and handling and storage costs were $10.9 million and $21.4 million for the three and six months ended September 30, 2016, respectively, and $10.4 million and $19.1 million for the three and six months ended September 30, 2015, respectively. Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees. Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period. Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income. Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. Recently Issued Accounting Standards In August 2016, the FASB issued Accounting Standards Update ("ASU") 2016-15, Classification of Certain Cash Receipts and Cash Payments . The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016-15 is not expected to have a material impact on our Consolidated Financial Statements. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers . The amendments do not change the core principle of the guidance in FASB ASC 606, discussed below. Rather, the amendments in this update affect only certain narrow aspects of FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on identifying performance obligations and licensing in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . The amendments in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards, and classification on the statement of cash flows. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on principals versus agent considerations in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of ASU 2015-11 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Acquisitions

Acquisitions	6 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions Acquisition of DenTek On February 5, 2016, the Company completed the acquisition of DenTek Holdings, Inc. ("DenTek"), a privately-held marketer and distributor of specialty oral care products. The closing was finalized pursuant to the terms of the merger agreement, announced November 23, 2015, under which Prestige agreed to acquire DenTek from its stockholders for a purchase price of $228.3 million . The acquisition expands Prestige's portfolio of brands, strengthens its existing oral care platform and increases its geographic reach in parts of Europe. The Company financed the transaction with a combination of available cash on hand, available cash from its Asset Based Loan revolver, and financing of an additional unsecured bridge loan. The DenTek brands are primarily included in the Company's North American and International OTC Healthcare segments. The DenTek acquisition was accounted for in accordance with the Business Combinations topic of the FASB ASC 805, which requires that the total cost of an acquisition be allocated to the tangible and intangible assets acquired and liabilities assumed based upon their respective fair values at the date of acquisition. We prepared an analysis of the fair values of the assets acquired and liabilities assumed as of the date of acquisition. The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date. (In thousands) February 5, 2016 Cash acquired $ 1,359 Accounts receivable 9,187 Inventories 14,304 Deferred income taxes 3,303 Prepaids and other current assets 6,728 Property, plant and equipment, net 3,555 Goodwill 76,529 Intangible assets, net 206,700 Total assets acquired 321,665 Accounts payable 3,261 Accrued expenses 16,488 Deferred income tax liabilities - long term 73,573 Total liabilities assumed 93,322 Total purchase price $ 228,343 Based on this preliminary analysis, we allocated $179.8 million to non-amortizable intangible assets and $26.9 million to amortizable intangible assets. We are amortizing the purchased amortizable intangible assets on a straight-line basis over an estimated weighted average useful life of 18.5 years. The weighted average remaining life for amortizable intangible assets at September 30, 2016 was 18.0 years. We also recorded goodwill of $76.5 million based on the amount by which the purchase price exceeded the fair value of the net assets acquired. Goodwill is not deductible for income tax purposes. The pro forma effect of this acquisition on revenues and earnings was not material.

Divestitures and Assets Held Fo

Divestitures and Assets Held For Sale	6 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Divestitures and Assets Held For Sale	Divestitures and Assets Held for Sale Divestitures Late in the first quarter of fiscal 2017, the Company was approached and discussed the potential to sell certain assets. Prior to these discussions, the Company did not contemplate any divestitures, and the Company did not commit to any course of action to divest any of the assets until entering into an agreement on June 29, 2016 to sell Pediacare , New Skin and Fiber Choice, which were reported under the North American OTC Healthcare segment in the Cough & Cold, Dermatologicals and Gastrointestinal product groups, respectively. On July 7, 2016, we completed the sale of the Pediacare, New Skin and Fiber Choice brands for $40.0 million plus the cost of inventory. As a result, we received approximately $40.1 million including the cost of preliminary inventory of $2.6 million , less certain immaterial holdbacks, which will be paid upon meeting certain criteria as defined in the agreement and within approximately 18 months following the closing date of the transaction. During the six months ended September 30, 2016, we recorded a preliminary pre-tax loss on sale of $56.2 million . The proceeds were used to repay debt and related income taxes due on the disposition. The following table sets forth the components of the assets sold and the pre-tax loss recognized on the sale. (In thousands) July 7, Components of assets sold: Inventory $ 2,380 Intangible assets, net 91,208 Goodwill 2,920 Assets sold 96,508 Total purchase price to be received 42,380 54,128 Costs to sell 2,018 Pre-tax loss on sale $ 56,146 Concurrent with the completion of the sale of these brands, we entered into a transitional services agreement with the buyer, whereby we agreed to provide the buyer with various services, including marketing, operations, finance and other services, from the date of the acquisition through January 7, 2017. We also entered into an option agreement with the buyer to purchase Dermoplast at a specified earnings multiple as defined in the agreement. The buyer paid a $1.25 million deposit in September 2016, and has recently notified us of its election to exercise the option. We currently expect that this transaction will be completed by March 31, 2017, although the buyer has until December 31, 2017 to complete the transaction. Accordingly, the Dermoplast transaction is not included in the table above and the $1.25 million option deposit is included in our other accrued liabilities at September 30, 2016. The inventory and other assets related to Dermoplast are included in the assets held for sale table below. Assets Held for Sale In connection with the divestiture above, the buyer recently notified us of its intention to exercise its option and purchase the Dermoplast brand. As such, we expect to conclude this transaction by March 31, 2017 and the following table sets forth the assets held for sale as of September 30, 2016 related to our Dermoplast brand. (In thousands) September 30, Components of assets held for sale: Inventory $ 619 Intangible assets, net 31,030 Goodwill 4,751 Assets Held for Sale $ 36,400

Accounts Receivable

Accounts Receivable	6 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Accounts Receivable	Accounts Receivable Accounts receivable consist of the following: (In thousands) September 30, March 31, Components of Accounts Receivable Trade accounts receivable $ 103,744 $ 105,592 Other receivables 1,011 1,261 104,755 106,853 Less allowances for discounts, returns and uncollectible accounts (11,886 ) (11,606 ) Accounts receivable, net $ 92,869 $ 95,247

Inventories

Inventories	6 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: (In thousands) September 30, March 31, Components of Inventories Packaging and raw materials $ 7,552 $ 7,563 Finished goods 90,407 83,700 Inventories $ 97,959 $ 91,263 Inventories are carried and depicted above at the lower of cost or market value, which includes a reduction in inventory values of $4.5 million and $4.8 million at September 30, 2016 and March 31, 2016 , respectively, related to obsolete and slow-moving inventory.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: (In thousands) September 30, March 31, Components of Property and Equipment Machinery $ 8,122 $ 7,734 Computer equipment 12,928 12,793 Furniture and fixtures 2,501 2,445 Leasehold improvements 7,372 7,389 30,923 30,361 Accumulated depreciation (17,191 ) (14,821 ) Property and equipment, net $ 13,732 $ 15,540 We recorded depreciation expense of $1.5 million and $3.0 million for the three and six months ended September 30, 2016, respectively. We recorded depreciation expense of $1.2 million and $2.5 million for the three and six months ended September 30, 2015, respectively.

Goodwill

Goodwill	6 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2016 $ 330,615 $ 22,776 $ 6,800 $ 360,191 Reductions (7,670 ) — (555 ) (8,225 ) Effects of foreign currency exchange rates — (304 ) — (304 ) Balance — September 30, 2016 $ 322,945 $ 22,472 $ 6,245 $ 351,662 In August 2016, we sold the rights to use of the Comet brand in certain geographic areas (see Note 8 below for further information) and reduced goodwill by $0.6 million as a result. On July 7, 2016, we completed the sale of Pediacare , New Skin and Fiber Choice ( see Note 3 above for further details) for $40.0 million plus the cost of inventory and received $40.1 million including preliminary inventory, less certain immaterial holdbacks, and reduced goodwill by $2.9 million as a result. In addition, as discussed in Note 3, in connection with this sale, the buyer has exercised its option and notified us of its intention to purchase Dermoplast . As such, we have reclassified $4.8 million of goodwill to assets held for sale as of September 30, 2016. Under accounting guidelines, goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. On an annual basis during the fourth quarter of each fiscal year, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of the values assigned to goodwill and tests for impairment. At February 29, 2016 , during our annual test for goodwill impairment, there were no indicators of impairment under the analysis. Accordingly, no impairment charge was recorded in fiscal 2016. We utilize the discounted cash flow method to estimate the fair value of our reporting units as part of the goodwill impairment test. We also considered our market capitalization at February 29, 2016 , which was the date of our annual review, as compared to the aggregate fair values of our reporting units, to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. As of September 30, 2016, no events have occurred that would indicate potential impairment of goodwill.

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Totals Gross Carrying Amounts Balance — March 31, 2016 $ 2,020,046 $ 417,880 $ 2,437,926 Reductions (77,248 ) (60,103 ) (137,351 ) Effects of foreign currency exchange rates (380 ) (103 ) (483 ) Balance — September 30, 2016 1,942,418 357,674 2,300,092 Accumulated Amortization Balance — March 31, 2016 — 115,203 115,203 Additions — 9,865 9,865 Reductions — (6,102 ) (6,102 ) Effects of foreign currency exchange rates — (2 ) (2 ) Balance — September 30, 2016 — 118,964 118,964 Intangible assets, net - September 30, 2016 $ 1,942,418 $ 238,710 $ 2,181,128 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,755,636 $ 215,817 $ 1,971,453 International OTC Healthcare 85,520 1,087 86,607 Household Cleaning 101,262 21,806 123,068 Intangible assets, net - September 30, 2016 $ 1,942,418 $ 238,710 $ 2,181,128 Historically, we received royalty income from the licensing of the names of certain of our brands in geographic areas or markets in which we do not directly compete. We have had royalty agreements for our Comet brand for several years, which included options on behalf of the licensee to purchase license rights in certain geographic areas and markets in perpetuity. In December 2014, we amended these agreements and we sold rights to use of the Comet brand in certain Eastern European countries to a third-party licensee in exchange for $10.0 million as a partial early buyout. The amended agreement provided that we would continue to receive royalty payments of $1.0 million per quarter for the remaining geographic areas and also granted the licensee an option to acquire the license rights in the remaining geographic areas anytime after June 30, 2016. In July 2016, the licensee elected to exercise its option. In August 2016, we received $ 11.0 million for the purchase of the remaining license rights and, as a result, we recorded a pre-tax gain of $1.2 million and reduced our indefinite-lived trademarks by $9.0 million . Furthermore, the licensee is no longer required to make additional royalty payments to us, and as a result, our future royalty income will be reduced accordingly. On July 7, 2016, we completed the sale of Pediacare , New Skin and Fiber Choice (see Note 3 above for further details) brands for $40.0 million plus the cost of inventory and received $40.1 million including the cost of preliminary inventory, less certain immaterial holdbacks, and reduced our indefinite and finite-lived trademarks by $37.2 million and $54.0 million , respectively. During the six months ended September 30, 2016, we recorded a preliminary pre-tax loss of $56.2 million on the sale of these brands. In addition, as discussed in Note 3, in connection with this sale, the buyer has exercised its option and notified us of its intention to purchase Dermoplast . As such, we have reclassified $31.0 million of indefinite-lived intangible assets to assets held for sale as of September 30, 2016. Under accounting guidelines, indefinite-lived assets are not amortized, but must be tested for impairment annually, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of the asset below the carrying amount. Additionally, at each reporting period, an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and are also tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value. On an annual basis during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recoverable, management performs a review of both the values and, if applicable, useful lives assigned to intangible assets and tests for impairment. We utilize the excess earnings method to estimate the fair value of our individual indefinite-lived intangible assets. We also considered our market capitalization at February 29, 2016 , which was the date of our annual review. The estimates and assumptions made in assessing the fair value of our reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances, or reductions in advertising and promotion may require an impairment charge to be recorded in the future. The weighted average remaining life for finite-lived intangible assets at September 30, 2016 was approximately 13.1 years, and the amortization expense for the three and six months ended September 30, 2016 was $4.6 million and $9.9 million , respectively. At September 30, 2016 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2017 (Remaining six months ending March 31, 2017) $ 9,113 2018 18,062 2019 18,062 2020 18,062 2021 17,640 Thereafter 157,771 $ 238,710

Other Accrued Liabilities

Other Accrued Liabilities	6 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities Other accrued liabilities consist of the following: (In thousands) September 30, March 31, Accrued marketing costs $ 29,938 $ 26,373 Accrued compensation costs 5,572 9,574 Accrued broker commissions 965 1,497 Income taxes payable 10,284 3,675 Accrued professional fees 3,050 1,787 Deferred rent 690 836 Accrued production costs 3,023 3,324 Accrued lease termination costs 384 448 Income tax related payable 6,354 6,354 Other accrued liabilities 6,746 5,856 $ 67,006 $ 59,724

Long-Term Debt

Long-Term Debt	6 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt 2012 Term Loan and 2012 ABL Revolver: On January 31, 2012, Prestige Brands, Inc. (the "Borrower") entered into a new senior secured credit facility, which consists of (i) a $660.0 million term loan facility (the “2012 Term Loan”) with a 7 -year maturity and (ii) a $50.0 million asset-based revolving credit facility (the “2012 ABL Revolver”) with a 5 -year maturity. In subsequent years, we have utilized portions of our accordion feature to increase the amount of our borrowing capacity under the 2012 ABL Revolver by $85.0 million to $135.0 million and reduced our borrowing rate on the 2012 ABL Revolver by 0.25% (discussed below). The 2012 Term Loan was issued with an original issue discount of 1.5% of the principal amount thereof, resulting in net proceeds to the Borrower of $650.1 million . In connection with these loan facilities, we incurred $20.6 million of costs, which were capitalized as deferred financing costs and are being amortized over the terms of the facilities. The 2012 Term Loan is unconditionally guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. On February 21, 2013, we entered into Amendment No. 1 ("Term Loan Amendment No. 1") to the 2012 Term Loan. Term Loan Amendment No. 1 provided for the refinancing of all of the Borrower's existing Term B Loans with new Term B-1 Loans (the "Term B-1 Loans"). The interest rate on the Term B-1 Loans under Term Loan Amendment No. 1 was based, at our option, on a LIBOR rate plus a margin of 2.75% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin. The new Term B-1 Loans would have matured on the same date as the Term B Loans' original maturity date. In addition, Term Loan Amendment No. 1 provided the Borrower with certain additional capacity to prepay subordinated debt, the Company's 8.125% senior notes due in 2020 and certain other unsecured indebtedness permitted to be incurred under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver. In connection with Term Loan Amendment No. 1, during the fourth quarter ended March 31, 2013, we recognized a $1.4 million loss on the extinguishment of debt. On September 3, 2014, we entered into Amendment No. 2 ("Term Loan Amendment No. 2") to the 2012 Term Loan. Term Loan Amendment No. 2 provided for (i) the creation of a new class of Term B-2 Loans under the 2012 Term Loan (the "Term B-2 Loans") in an aggregate principal amount of $720.0 million , (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility and financial maintenance covenant relief, and (iii) an interest rate on (x) the Term B-1 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.125% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin, and (y) the Term B-2 Loans that was based, at our option, on a LIBOR rate plus a margin of 3.50% per annum, with a LIBOR floor of 1.00% , or an alternate base rate, with a floor of 2.00% , plus a margin (with a margin step-down to 3.25% per annum, based upon achievement of a specified secured net leverage ratio). Also, on September 3, 2014, we entered into Amendment No. 3 ("ABL Amendment No. 3") to the 2012 ABL Revolver. ABL Amendment No. 3 provided for (i) a $40.0 million increase in revolving commitments under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment and debt incurrence flexibility. Borrowings under the 2012 ABL Revolver, as amended, bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., and (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs. The applicable margin for borrowings under the 2012 ABL Revolver may be increased to 2.00% or 2.25% for LIBOR borrowings and 1.00% or 1.25% for base-rate borrowings, depending on average excess availability under the 2012 ABL Revolver during the prior fiscal quarter. In addition to paying interest on outstanding principal under the 2012 ABL Revolver, we are required to pay a commitment fee to the lenders under the 2012 ABL Revolver in respect of the unutilized commitments thereunder. The initial commitment fee rate is 0.50% per annum. The commitment fee rate will be reduced to 0.375% per annum at any time when the average daily unused commitments for the prior quarter is less than a percentage of total commitments by an amount set forth in the credit agreement covering the 2012 ABL Revolver. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. On May 8, 2015, we entered into Amendment No. 3 ("Term Loan Amendment No. 3") to the 2012 Term Loan. Term Loan Amendment No. 3 provided for (i) the creation of a new class of Term B-3 Loans under the 2012 Term Loan (the "Term B-3 Loans") in an aggregate principal amount of $852.5 million , which combined the outstanding balances of the Term B-1 Loans of $207.5 million and the Term B-2 Loans of $645.0 million , and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief. The maturity date of the Term B-3 Loans remains the same as the Term B-2 Loans' original maturity date of September 3, 2021. The 2012 Term Loan, as amended, bears interest at a rate per annum equal to an applicable margin plus, at our option, either (i) a base rate determined by reference to the highest of (a) the Federal Funds rate plus 0.50% , (b) the prime rate of Citibank, N.A., (c) the LIBOR rate determined by reference to the cost of funds for U.S. dollar deposits for an interest period of one month, adjusted for certain additional costs, plus 1.00% and (d) a floor of 1.75% or (ii) a LIBOR rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing, adjusted for certain additional costs, with a floor of 0.75% . For the six months ended September 30, 2016, the average interest rate on the 2012 Term Loan was 5.0% . On June 9, 2015, we entered into Amendment No. 4 (“ABL Amendment No. 4”) to the 2012 ABL Revolver. ABL Amendment No. 4 provided for (i) a $35.0 million increase in the accordion feature under the 2012 ABL Revolver and (ii) increased flexibility under the credit agreement governing the 2012 Term Loan and 2012 ABL Revolver, including additional investment, restricted payment, and debt incurrence flexibility and financial maintenance covenant relief and (iii) extended the maturity date of the 2012 ABL Revolver to June 9, 2020, which is five years from the effective date. We may voluntarily repay outstanding loans under the 2012 ABL Revolver at any time without a premium or penalty. For the six months ended September 30, 2016, the average interest rate on the amounts borrowed under the 2012 ABL Revolver was 2.4% . In connection with the DenTek acquisition on February 5, 2016, we entered into Amendment No. 5 (“ABL Amendment No. 5”) to the 2012 ABL Revolver. ABL Amendment No. 5 temporarily suspended certain financial and related reporting covenants in the 2012 ABL Revolver until the earliest of (i) the date that was 60 calendar days following February 4, 2016, (ii) the date upon which certain of DenTek’s assets were included in the Company’s borrowing base under the 2012 ABL Revolver and (iii) the date upon which the Company received net proceeds from an offering of debt securities. 2013 Senior Notes: On December 17, 2013, the Borrower issued $400.0 million of senior unsecured notes, with an interest rate of 5.375% and a maturity date of December 15, 2021 (the "2013 Senior Notes"). The Borrower may redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. The 2013 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its 100% domestic owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2013 Senior Notes offering, we incurred $7.2 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2013 Senior Notes. 2016 Senior Notes: On February 19, 2016, the Borrower completed the sale of $350.0 million aggregate principal amount of 6.375% senior notes due 2024 (the “2016 Senior Notes”), pursuant to a purchase agreement, dated February 16, 2016, among the Borrower, the guarantors party thereto (the “Guarantors”) and the initial purchasers party thereto. The 2016 Senior Notes are guaranteed by Prestige Brands Holdings, Inc. and certain of its domestic 100% owned subsidiaries, other than the Borrower. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the Guarantors to obtain funds from their subsidiaries or to make payments to the Borrower or the Company. In connection with the 2016 Senior Notes offering, we incurred $5.5 million of costs, which were capitalized as deferred financing costs and are being amortized over the term of the 2016 Senior Notes. The 2016 Senior Notes were issued pursuant to an indenture, dated February 19, 2016 (the “Indenture”). The Indenture provides, among other things, that interest will be payable on the 2016 Senior Notes on March 1 and September 1 of each year, beginning on September 1, 2016, until their maturity date of March 1, 2024. The 2016 Senior Notes are senior unsecured obligations of the Borrower. Redemptions and Restrictions: At any time prior to December 15, 2016, we have the option to redeem the 2013 Senior Notes in whole or in part at a redemption price equal to 100% of the principal amount of notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the indenture governing the 2013 Senior Notes, together with accrued and unpaid interest, if any, to the date of redemption. On or after December 15, 2016, we have the option to redeem some or all of the 2013 Senior Notes at redemption prices set forth in the indenture governing the 2013 Senior Notes. In addition, at any time prior to December 15, 2016, we have to the option to redeem up to 35% of the aggregate principal amount of the 2013 Senior Notes at a redemption price equal to 105.375% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, with the net cash proceeds of certain equity offerings, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the indenture governing the 2013 Senior Notes, the Borrower will be required to make an offer to purchase the 2013 Senior Notes at a price equal to 101% of the aggregate principal amount of the 2013 Senior Notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. The Borrower has the option to redeem all or a portion of the 2016 Senior Notes at any time on or after March 1, 2019 at the redemption prices set forth in the Indenture, plus accrued and unpaid interest, if any. The Borrower may also redeem all or any portion of the 2016 Senior Notes at any time prior to March 1, 2019, at a price equal to 100% of the aggregate principal amount of the notes redeemed, plus an applicable "make-whole premium" calculated as set forth in the Indenture, and accrued and unpaid interest, if any, to the date of redemption. In addition, before March 1, 2019, the Borrower may redeem up to 40% of the aggregate principal amount of the 2016 Senior Notes with the net proceeds of certain equity offerings at the redemption price set forth in the Indenture, provided that certain conditions are met. Subject to certain limitations, in the event of a change of control, as defined in the Indenture, the Borrower will be required to make an offer to purchase the 2016 Senior Notes at a price equal to 101% of the aggregate principal amount of the notes repurchased, plus accrued and unpaid interest, if any, to the date of repurchase. The indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain provisions that restrict us from undertaking specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchases of common shares outstanding, changes of control, incurrences of indebtedness, issuance of equity, creation of liens, making of loans and transactions with affiliates. Additionally, the credit agreement with respect to the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes contain cross-default provisions, whereby a default pursuant to the terms and conditions of certain indebtedness will cause a default on the remaining indebtedness under the credit agreement governing the 2012 Term Loan and the 2012 ABL Revolver and the indentures governing the 2013 Senior Notes and the 2016 Senior Notes. At September 30, 2016, we were in compliance with the covenants under our long-term indebtedness. At September 30, 2016, we had an aggregate of $1.1 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $22.3 million of unamortized debt costs included in long-term debt costs, the total of which is comprised of $5.0 million related to the 2013 Senior Notes, $5.1 million related to the 2016 Senior Notes, and $12.2 million related to the 2012 Term Loan. At March 31, 2016, we had an aggregate of $1.3 million of unamortized debt costs related to the 2012 ABL Revolver included in other long-term assets, and $27.2 million of unamortized debts costs included in long-term debt costs, the total of which is comprised of $5.4 million related to the 2013 Senior Notes, $5.4 million related to the 2016 Senior Notes, and $16.4 million related to the 2012 Term Loan. At September 30, 2016, we had $65.0 million outstanding on the 2012 ABL Revolver and a borrowing capacity of $68.2 million . Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, March 31, 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 350,000 $ 350,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 687,000 817,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. 65,000 85,000 Total long-term debt (including current portion) 1,502,000 1,652,500 Current portion of long-term debt — — Long-term debt 1,502,000 1,652,500 Less: unamortized debt costs (22,337 ) (27,191 ) Long-term debt, net $ 1,479,663 $ 1,625,309 At September 30, 2016, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2017 (remaining six months ending March 31, 2017) $ — 2018 — 2019 — 2020 — 2021 65,000 Thereafter 1,437,000 $ 1,502,000

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts. The Fair Value Measurements and Disclosures topic of the FASB ASC 820 requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures topic established market (observable inputs) as the preferred source of fair value, to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs. Based upon the above, the following fair value hierarchy was created: Level 1 - Quoted market prices for identical instruments in active markets; Level 2 - Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not considered active; and Level 3 - Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market participant. The market values have been determined based on market values for similar instruments adjusted for certain factors. As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-3 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at September 30, 2016 and March 31, 2016). September 30, 2016 March 31, 2016 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 350,000 $ 371,000 $ 350,000 $ 363,125 2013 Senior Notes 400,000 414,000 400,000 408,000 Term B-3 Loans 687,000 693,011 817,500 818,522 2012 ABL Revolver 65,000 65,000 85,000 85,000 At September 30, 2016 and March 31, 2016, we did not have any assets or liabilities measured in Level 1 or 3.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders' Equity The Company is authorized to issue 250.0 million shares of common stock, $0.01 par value per share, and 5.0 million shares of preferred stock, $0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof. Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of outstanding stock having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through September 30, 2016 . During each of the three months ended September 30, 2016 and 2015, we did not repurchase any shares of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. During the six months ended September 30, 2016 and 2015, we repurchased 24,988 shares and 39,429 shares, respectively, of restricted common stock from our employees pursuant to the provisions of various employee restricted stock awards. The repurchases for the six months ended September 30, 2016 and 2015 were at an average price of $55.82 and $41.66 , respectively. All of the repurchased shares have been recorded as treasury stock.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at September 30, 2016 and March 31, 2016 : September 30, March 31, (In thousands) 2016 2016 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (26,646 ) $ (23,525 ) Accumulated other comprehensive loss, net of tax $ (26,646 ) $ (23,525 )

Earnings Per Share

Earnings Per Share	6 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed based on the weighted-average number of shares of common stock outstanding plus the effect of potentially dilutive common shares outstanding during the period using the treasury stock method, which includes stock options and restricted stock units. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share. The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2016 2015 2016 2015 Numerator Net income $ 32,195 $ 31,803 $ 26,664 $ 57,976 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,993 52,803 52,941 52,676 Dilutive effect of unvested restricted stock units and options issued to employees and directors 352 348 388 379 Denominator for diluted earnings per share 53,345 53,151 53,329 53,055 Earnings per Common Share: Basic net earnings per share $ 0.61 $ 0.60 $ 0.50 $ 1.10 Diluted net earnings per share $ 0.60 $ 0.60 $ 0.50 $ 1.09 For each of the three months ended September 30, 2016 and 2015, there were 0.2 million shares attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive. For each of the six months ended September 30, 2016 and 2015, there were 0.2 million shares attributable to outstanding stock-based awards that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-Based Compensation	Share-Based Compensation In connection with our initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan (the “Plan”), which provides for grants of up to a maximum of 5.0 million shares of restricted stock, stock options, restricted stock units and other equity-based awards. In June 2014, the Board of Directors approved, and in July 2014, the stockholders ratified, an increase of an additional 1.8 million shares of our common stock for issuance under the Plan, increased the maximum number of shares subject to stock options that may be awarded to any one participant under the Plan during any 12-month period from 1.0 million to 2.5 million shares, and extended the term of the Plan by ten years to February 2025. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. During the three and six months ended September 30, 2016 , pre-tax share-based compensation costs charged against income were $2.0 million and $3.9 million , respectively, and the related income tax benefit recorded was $0.5 million and $1.2 million , respectively. During the three and six months ended September 30, 2015, pre-tax share-based compensation costs charged against income were $2.0 million and $5.0 million , respectively, and the related income tax benefit recorded was $0.7 million and $1.8 million , respectively. At September 30, 2016 , there were $12.4 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan, based on management's estimate of the shares that will ultimately vest. We expect to recognize such costs over a weighted-average period of 1.0 years. The total fair value of options and restricted stock units vested during the six months ended September 30, 2016 and 2015 was $6.0 million and $6.5 million , respectively. For the six months ended September 30, 2016 and 2015, we issued 92,718 and 153,603 shares of restricted stock units, respectively, and received cash from the exercise of stock options of $3.4 million and $6.4 million , respectively. Accordingly, we realized $1.7 million and $3.5 million , respectively, in tax benefits from the tax deductions resulting from these restricted stock issuances and stock option exercises. At September 30, 2016 , there were 2.4 million shares available for issuance under the Plan. On May 9, 2016, the Compensation Committee of our Board of Directors granted 49,064 shares of restricted stock units and stock options to acquire 224,843 shares of our common stock to certain executive officers and employees under the Plan. All of the shares of restricted stock units vest in their entirety on the three -year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $57.18 per share, which is equal to the closing price for our common stock on the date of the grant. Termination of employment prior to vesting will result in forfeiture of the unvested restricted common stock units and the unvested stock options. Vested stock options will remain exercisable by the employee after termination, subject to the terms of the Plan. On September 12, 2016, we announced that Christine Sacco had been appointed as Chief Financial Officer of the Company, effective that same day. In connection with Ms. Sacco's appointment as Chief Financial Officer on September 12, 2016, the Company executed an offer letter with Ms. Sacco, which sets forth the terms of her compensation as approved by the Compensation Committee of the Board of Directors. In accordance with the terms of her offer letter, the Company granted Ms. Sacco 5,012 shares of restricted stock units and stock options to acquire 25,746 shares of our common stock under the Plan.The restricted stock units vest in their entirety on the three-year anniversary of the date of grant. Upon vesting, the units will be settled in shares of our common stock. The stock options will vest 33.3% per year over three years and are exercisable for up to ten years from the date of grant. These stock options were granted at an exercise price of $47.39 per share, which is equal to the closing price of our common stock on the date of grant. Restricted Shares Restricted shares granted to employees under the Plan generally vest in three to five years, primarily upon the attainment of certain time vesting thresholds, and may also be contingent on the attainment of certain performance goals of the Company, including revenue and earnings before income taxes, depreciation and amortization targets. The restricted stock unit awards provide for accelerated vesting if there is a change of control, as defined in the Plan. The restricted stock units granted to employees generally vest in their entirety on the three -year anniversary of the date of the grant. Upon vesting, the units will be settled in shares of our common stock. Termination of employment prior to vesting will result in forfeiture of the restricted stock units, unless otherwise accelerated by the Compensation Committee. The restricted stock units granted to directors vest in their entirety one year after the date of grant so long as membership on the Board of Directors continues through the vesting date, and will be settled by delivery to the director of one share of common stock of the Company for each vested restricted stock unit promptly following the earliest of the director's (i) death, (ii) disability or (iii) the six -month anniversary of the date on which the director's Board membership ceases for reasons other than death or disability. At our annual meeting date on August 2, 2016, each of our six independent members of the Board of Directors received a grant of 1,896 restricted stock units under the Plan. Additionally, on May 26, 2016 , the Compensation Committee granted 346 restricted stock units to a newly appointed Board member. The fair value of the restricted stock units is determined using the closing price of our common stock on the date of the grant. The weighted-average grant-date fair value of restricted stock units granted during the six months ended September 30, 2016 and 2015 was $55.65 and $42.20 , respectively. A summary of the Company's restricted stock units granted under the Plan is presented below: Restricted Stock Units Shares (in thousands) Weighted- Average Grant-Date Fair Value Six months ended September 30, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 259.5 42.20 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at September 30, 2015 466.8 35.03 Vested at September 30, 2015 69.8 14.76 Six months ended September 30, 2016 Vested and nonvested at March 31, 2016 467.8 $ 35.22 Granted 65.8 55.65 Vested and issued (92.7 ) 28.47 Forfeited (91.0 ) 41.69 Vested and nonvested at September 30, 2016 349.9 39.16 Vested at September 30, 2016 63.4 20.12 Options The Plan provides that the exercise price of options granted shall be no less than the fair market value of the Company's common stock on the date the options are granted. Options granted have a term of no greater than ten years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally three to five years. The option awards provide for accelerated vesting in the event of a change in control, as defined in the Plan. Termination of employment prior to vesting will result in forfeiture of the unvested stock options. Vested stock options will remain exercisable by the employee after termination of employment, subject to the terms in the Plan. The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model that uses the assumptions noted in the table below. Expected volatilities are based on the historical volatility of our common stock and other factors, including the historical volatilities of comparable companies. We use appropriate historical data, as well as current data, to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from our historical experience, management's estimates, and consideration of information derived from the public filings of companies similar to us, and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted options. The weighted-average grant-date fair values of the options granted during the six months ended September 30, 2016 and 2015 were $21.87 and $17.10 , respectively. Six months ended September 30, 2016 2015 Expected volatility 37.8 % 40.2 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 1.7 % A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six months ended September 30, 2015 Outstanding at March 31, 2015 871.2 $ 23.40 Granted 200.1 41.80 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.16 Outstanding at September 30, 2015 732.3 30.42 8.1 $ 10,816 Exercisable at September 30, 2015 319.5 21.91 7.0 $ 7,430 Six months ended September 30, 2016 Outstanding at March 31, 2016 727.7 $ 30.70 Granted 250.6 56.17 Exercised (107.1 ) 31.97 Forfeited or expired (90.7 ) 42.56 Outstanding at September 30, 2016 780.5 37.33 7.5 $ 10,326 Exercisable at September 30, 2016 383.7 25.61 6.5 $ 8,693 The aggregate intrinsic value of options exercised in the six months ended September 30, 2016 was $2.4 million .

Income Taxes

Income Taxes	6 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income taxes are recorded in our quarterly financial statements based on our estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The effective tax rates used in the calculation of income taxes were 35.9% and 35.4% for the three months ended September 30, 2016 and 2015, respectively. The effective rates used in the calculation of income taxes were 35.5% and 35.2% for the six months ended September 30, 2016 and 2015, respectively. The increase in the effective tax rate for the three and six months ended September 30, 2016 was primarily due to non-deductible goodwill associated with the sale of rights to use Comet in certain geographic areas. See Note 8 above for further information on the sale of rights to use Comet . During the six months ended September 30, 2016, we realized a net reduction to our deferred tax liability of $27.5 million as a result of the sale of Pediacare , New Skin and Fiber Choice . At September 30, 2016, a 100% owned subsidiary of the Company had a net operating loss carryforward of approximately $14.0 million ( $5.0 million , tax effected), which may be used to offset future taxable income of the consolidated group and begins to expire in 2025. The Company expects to fully utilize the loss carryover before it expires. The net operating loss carryforward is subject to an annual limitation as to usage under Internal Revenue Code Section 382 of approximately $33.6 million . The balance in our uncertain tax liability was $4.1 million at September 30, 2016 and March 31, 2016. We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. We did not incur any material interest or penalties related to income taxes in any of the periods presented.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We are involved from time to time in legal matters and other claims incidental to our business. We review outstanding claims and proceedings internally and with external counsel as necessary to assess the probability and amount of a potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). We believe the resolution of routine legal matters and other claims incidental to our business, taking our reserves into account, will not have a material adverse effect on our business, financial condition, or results of operations. Lease Commitments We have operating leases for office facilities and equipment in New York and other locations, which expire at various dates through fiscal 2022. These amounts have been included in the table below. The following summarizes future minimum lease payments for our operating leases as of September 30, 2016 : (In thousands) Year Ending March 31, Facilities Equipment Total (a) 2017 (Remaining six months ending March 31, 2017) $ 1,048 $ 76 $ 1,124 2018 2,029 152 2,181 2019 2,023 152 2,175 2020 1,848 89 1,937 2021 903 — 903 Thereafter 59 — 59 $ 7,910 $ 469 $ 8,379 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.0 million due to us in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) September 30, 2016 March 31, 2016 Minimum lease payments $ 8,379 $ 8,434 Less: Sublease rentals (1,036 ) (1,165 ) $ 7,343 $ 7,269 Rent expense for the three months ended September 30, 2016 and 2015 was $0.5 million and $0.4 million , respectively. Rent expense for the six months ended September 30, 2016 and 2015 was $1.1 million and $0.8 million , respectively. Purchase Commitments Effective November 1, 2009, we entered into a ten year supply agreement for the exclusive manufacture of a portion of one of our Household Cleaning products. Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2017 (Remaining six months ending March 31, 2017) 518 2018 1,013 2019 982 2020 559 2021 — $ 3,072

Concentrations of Risk

Concentrations of Risk	6 Months Ended
	Sep. 30, 2016
Risks and Uncertainties [Abstract]
Concentrations of Risk	Concentrations of Risk Our revenues are concentrated in the areas of OTC Healthcare and Household Cleaning products. We sell our products to mass merchandisers, food and drug stores, and convenience, dollar and club stores. During the three and six months ended September 30, 2016 , approximately 41.6% and 42.0% , respectively, of our total revenues were derived from our five top selling brands. During the three and six months ended September 30, 2015, approximately 41.7% and 42.8% , respectively, of our total revenues were derived from our five top selling brands. Two customers, Walmart and Walgreens, accounted for more than 10% of our gross revenues for each of the periods presented. Walmart accounted for approximately 21.1% and 20.9% , respectively, of our gross revenues for the three and six months ended September 30, 2016 . Walmart accounted for approximately 19.6% and 19.7% , respectively, of our gross revenues for the three and six months ended September 30, 2015. Walgreens accounted for approximately 10.7% and 10.5% of gross revenues for the three and six months ended September 30, 2016, respectively. Walgreens accounted for approximately 10.0% and 9.7% of gross revenues for the three and six months ended September 30, 2015, respectively. At September 30, 2016 , approximately 23.5% and 10.6% of accounts receivable were owed by Walmart and Walgreens, respectively. We manage product distribution in the continental United States through a third-party distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage our inventories and could materially impair our ability to distribute our products to customers in a timely manner or at a reasonable cost. We could incur significantly higher costs and experience longer lead times associated with the distribution of our products to our customers during the time that it takes us to reopen or replace our distribution center. As a result, any such disruption could have a material adverse effect on our business, sales and profitability. At September 30, 2016 , we had relationships with 116 third-party manufacturers. Of those, we had long-term contracts with 49 manufacturers that produced items that accounted for approximately 78.8% of gross sales for the six months ended September 30, 2016 . At September 30, 2015 , we had relationships with 102 third-party manufacturers. Of those, we had long-term contracts with 48 manufacturers that produced items that accounted for approximately 81.3% of gross sales for the six months ended September 30, 2015 . The fact that we do not have long-term contracts with certain manufacturers means that they could cease manufacturing our products at any time and for any reason or initiate arbitrary and costly price increases, which could have a material adverse effect on our business and results from operations. Although we are in the process of negotiating long-term contracts with certain key manufacturers, we may not be able to reach a timely agreement, which could have a material adverse effect on our business and results of operations.

Business Segments

Business Segments	6 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Business Segments	Business Segments Segment information has been prepared in accordance with the Segment Reporting topic of the FASB ASC 280. Our current reportable segments consist of (i) North American OTC Healthcare, (ii) International OTC Healthcare and (iii) Household Cleaning. We evaluate the performance of our operating segments and allocate resources to these segments based primarily on contribution margin, which we define as gross profit less advertising and promotional expenses. The tables below summarize information about our reportable segments. Three Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 172,590 $ 18,802 $ 23,768 $ 215,160 Elimination of intersegment revenues (143 ) — — (143 ) Third-party segment revenues 172,447 18,802 23,768 215,017 Other revenues — 2 33 35 Total segment revenues 172,447 18,804 23,801 215,052 Cost of sales 65,402 7,096 18,589 91,087 Gross profit 107,045 11,708 5,212 123,965 Advertising and promotion 24,811 3,244 537 28,592 Contribution margin $ 82,234 $ 8,464 $ 4,675 95,373 Other operating expenses* 24,315 Operating income 71,058 Other expense 20,830 Income before income taxes 50,228 Provision for income taxes 18,033 Net income $ 32,195 *Other operating expenses for the three months ended September 30, 2016 includes a pre-tax loss on sale of assets of $0.7 million related to Pediacare , New Skin, and Fiber Choice and a pre-tax gain on sale of assets of $1.2 million associated with the sale of license rights in certain geographic areas pertaining to Comet . The assets and corresponding contribution margin associated with the pre-tax loss on sale of assets related to Pediacare , New Skin, and Fiber Choice are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment. Six Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 345,891 $ 34,602 $ 44,658 $ 425,151 Elimination of intersegment revenues (1,364 ) — — (1,364 ) Third-party segment revenues 344,527 34,602 44,658 423,787 Other revenues — 6 834 840 Total segment revenues 344,527 34,608 45,492 424,627 Cost of sales 129,636 14,044 35,391 179,071 Gross profit 214,891 20,564 10,101 245,556 Advertising and promotion 49,851 5,368 1,008 56,227 Contribution margin $ 165,040 $ 15,196 $ 9,093 189,329 Other operating expenses* 106,057 Operating income 83,272 Other expense 41,957 Income before income taxes 41,315 Provision for income taxes 14,651 Net income $ 26,664 *Other operating expenses for the six months ended September 30, 2016 includes a pre-tax loss on sale of assets of $56.2 million related to Pediacare , New Skin, and Fiber Choice and a pre-tax gain on sale of assets of $1.2 million associated with the sale of license rights in certain geographic areas pertaining to Comet . The assets and corresponding contribution margin associated with the pre-tax loss on sale of assets related to Pediacare , New Skin, and Fiber Choice are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment. Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 166,886 $ 15,954 $ 23,894 $ 206,734 Elimination of intersegment revenues (1,472 ) — — (1,472 ) Third-party segment revenues 165,414 15,954 23,894 205,262 Other revenues** — 6 797 803 Total segment revenues 165,414 15,960 24,691 206,065 Cost of sales** 61,497 6,094 18,534 86,125 Gross profit 103,917 9,866 6,157 119,940 Advertising and promotion 24,440 2,777 676 27,893 Contribution margin $ 79,477 $ 7,089 $ 5,481 92,047 Other operating expenses 22,149 Operating income 69,898 Other expense 20,667 Income before income taxes 49,231 Provision for income taxes 17,428 Net income $ 31,803 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 323,978 $ 29,410 $ 45,361 $ 398,749 Elimination of intersegment revenues (2,200 ) — — (2,200 ) Third-party segment revenues 321,778 29,410 45,361 396,549 Other revenues** 15 31 1,602 1,648 Total segment revenues 321,793 29,441 46,963 398,197 Cost of sales** 119,624 11,383 35,014 166,021 Gross profit 202,169 18,058 11,949 232,176 Advertising and promotion 47,635 5,500 1,180 54,315 Contribution margin $ 154,534 $ 12,558 $ 10,769 177,861 Other operating expenses 45,458 Operating income 132,403 Other expense 43,002 Income before income taxes 89,401 Provision for income taxes 31,425 Net income $ 57,976 ** Certain immaterial amounts relating to gross segment revenues, other revenues and cost of sales for each of the three and six months ended September 30, 2015 were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented. The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,993 $ 544 $ — $ 30,537 Cough & Cold 21,106 5,160 — 26,266 Women's Health 33,268 635 — 33,903 Gastrointestinal 16,280 6,088 — 22,368 Eye & Ear Care 22,934 2,989 — 25,923 Dermatologicals 22,952 567 — 23,519 Oral Care 24,368 2,820 — 27,188 Other OTC 1,546 1 — 1,547 Household Cleaning — — 23,801 23,801 Total segment revenues $ 172,447 $ 18,804 $ 23,801 $ 215,052 Six Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 58,119 $ 1,071 $ — $ 59,190 Cough & Cold 39,073 9,552 — 48,625 Women's Health 66,155 1,571 — 67,726 Gastrointestinal 35,386 10,344 — 45,730 Eye & Ear Care 48,941 5,785 — 54,726 Dermatologicals 45,650 1,238 — 46,888 Oral Care 48,179 5,037 — 53,216 Other OTC 3,024 10 — 3,034 Household Cleaning — — 45,492 45,492 Total segment revenues $ 344,527 $ 34,608 $ 45,492 $ 424,627 Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,694 $ 688 $ — $ 30,382 Cough & Cold 24,456 4,746 — 29,202 Women's Health 33,607 804 — 34,411 Gastrointestinal 19,061 5,342 — 24,403 Eye & Ear Care 24,163 3,578 — 27,741 Dermatologicals 23,197 611 — 23,808 Oral Care 9,733 189 — 9,922 Other OTC 1,503 2 — 1,505 Household Cleaning — — 24,691 24,691 Total segment revenues $ 165,414 $ 15,960 $ 24,691 $ 206,065 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 56,542 $ 1,218 $ — $ 57,760 Cough & Cold 44,215 9,252 — 53,467 Women's Health 66,515 1,504 — 68,019 Gastrointestinal 39,381 9,150 — 48,531 Eye & Ear Care 49,223 6,780 — 56,003 Dermatologicals 43,292 1,145 — 44,437 Oral Care 19,710 383 — 20,093 Other OTC 2,915 9 — 2,924 Household Cleaning — — 46,963 46,963 Total segment revenues $ 321,793 $ 29,441 $ 46,963 $ 398,197 During the three months ended September 30, 2016 and 2015, approximately 85.8% of our total segment revenues were from customers in the United States. During the six months ended September 30, 2016 and 2015, approximately 86.7% and 86.5% , respectively, of our total segment revenues were from customers in the United States. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented. During the three months ended September 30, 2016, our Canada and Australia sales accounted for approximately 5.4% and 5.9% , respectively, of our total segment revenues, while during the three months ended September 30, 2015, approximately 5.5% and 6.8% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. During the six months ended September 30, 2016, our Canada and Australia sales accounted for approximately 5.1% and 5.5% , respectively, of our total segment revenues, while during the six months ended September 30, 2015, approximately 5.3% and 6.3% , respectively, of our total segment revenues were attributable to sales to Canada and Australia. At September 30, 2016 and March 31, 2016, approximately 95.7% of our consolidated goodwill and intangible assets were located in the United States and approximately 4.3% were located in Australia and the United Kingdom. These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: September 30, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 322,945 $ 22,472 $ 6,245 $ 351,662 Intangible assets Indefinite-lived 1,755,636 85,520 101,262 1,942,418 Finite-lived 215,817 1,087 21,806 238,710 Intangible assets, net 1,971,453 86,607 123,068 2,181,128 Total $ 2,294,398 $ 109,079 $ 129,313 $ 2,532,790 March 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Goodwill $ 330,615 $ 22,776 $ 6,800 $ 360,191 Intangible assets Indefinite-lived 1,823,873 85,901 110,272 2,020,046 Finite-lived 277,762 2,237 22,678 302,677 Intangible assets, net 2,101,635 88,138 132,950 2,322,723 Total $ 2,432,250 $ 110,914 $ 139,750 $ 2,682,914

Condensed Consolidating Financi

Condensed Consolidating Financial Statements	6 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Financial Statements	Condensed Consolidating Financial Statements As described in Note 10, Prestige Brands Holdings, Inc., together with certain of our 100% owned subsidiaries, has fully and unconditionally guaranteed, on a joint and several basis, the obligations of Prestige Brands, Inc. (a 100% owned subsidiary of the Company) set forth in the indentures governing the 2016 Senior Notes and the 2013 Senior Notes, including the obligation to pay principal and interest with respect to the 2016 Senior Notes and the 2013 Senior Notes. The 100% owned subsidiaries of the Company that have guaranteed the 2016 Senior Notes and the 2013 Senior Notes are as follows: Prestige Services Corp., Prestige Brands Holdings, Inc. (a Virginia corporation), Prestige Brands International, Inc., Medtech Holdings, Inc., Medtech Products Inc., The Cutex Company, The Spic and Span Company, Blacksmith Brands, Inc., Insight Pharmaceuticals Corporation, Insight Pharmaceuticals, LLC, Practical Health Products, Inc., and DenTek Holdings, Inc. (collectively, the "Subsidiary Guarantors"). A significant portion of our operating income and cash flow is generated by our subsidiaries. As a result, funds necessary to meet Prestige Brands, Inc.'s debt service obligations are provided in part by distributions or advances from our subsidiaries. Under certain circumstances, contractual and legal restrictions, as well as the financial condition and operating requirements of our subsidiaries, could limit Prestige Brands, Inc.'s ability to obtain cash from our subsidiaries for the purpose of meeting our debt service obligations, including the payment of principal and interest on the 2016 Senior Notes and the 2013 Senior Notes. Although holders of the 2016 Senior Notes and the 2013 Senior Notes will be direct creditors of the guarantors of the 2016 Senior Notes and the 2013 Senior Notes by virtue of the guarantees, we have indirect subsidiaries located primarily in the United Kingdom, the Netherlands and Australia (collectively, the "Non-Guarantor Subsidiaries") that have not guaranteed the 2016 Senior Notes or the 2013 Senior Notes, and such subsidiaries will not be obligated with respect to the 2016 Senior Notes or the 2013 Senior Notes. As a result, the claims of creditors of the Non-Guarantor Subsidiaries will effectively have priority with respect to the assets and earnings of such companies over the claims of the holders of the 2016 Senior Notes and the 2013 Senior Notes. Presented below are supplemental Condensed Consolidating Balance Sheets as of September 30, 2016 and March 31, 2016 , Condensed Consolidating Statements of Income and Comprehensive Income for the three and six months ended September 30, 2016 and 2015 , and Condensed Consolidating Statements of Cash Flows for the six months ended September 30, 2016 and 2015 . Such consolidating information includes separate columns for: a) Prestige Brands Holdings, Inc., the parent, b) Prestige Brands, Inc., the Issuer or the Borrower, c) Combined Subsidiary Guarantors, d) Combined Non-Guarantor Subsidiaries, and e) Elimination entries necessary to consolidate the Company and all of its subsidiaries. The Condensed Consolidating Financial Statements are presented using the equity method of accounting for investments in our 100% owned subsidiaries. Under the equity method, the investments in subsidiaries are recorded at cost and adjusted for our share of the subsidiaries' cumulative results of operations, capital contributions, distributions and other equity changes. The elimination entries principally eliminate investments in subsidiaries and intercompany balances and transactions. The financial information in this note should be read in conjunction with the Consolidated Financial Statements presented and other notes related thereto contained in this Quarterly Report on Form 10-Q. In the second quarter of fiscal 2017, the Company determined that it had incorrectly recorded certain intercompany transactions relating to the first quarter of fiscal 2017 in the condensed consolidating financial statements. This resulted in an overstatement of equity in earnings of subsidiaries for Prestige Brands, Inc. (the “Issuer”) of $44.6 million and a net understatement of equity in earnings of subsidiaries for the eliminations of $44.6 million for the three months ended June 30, 2016.This item also resulted in corresponding adjustments to the investments in subsidiaries on the condensed consolidating balance sheet as of June 30, 2016 and adjustments to net income (loss) and equity in income of subsidiaries in the condensed consolidating statement of cash flows, although net cash provided by (used in) operating activities for the three months ended June 30, 2016 remained unchanged. These errors had no impact to the Company's consolidated balance sheet, consolidated statement of income or consolidated statement of cash flows. The Company assessed the materiality of these errors on the previously issued interim financial statements in accordance with SEC Staff Accounting Bulletin No. 99 and No. 108, and concluded that the errors were not material to the consolidated financial statements for the three months ended June 30, 2016. The Company appropriately reflected the intercompany transactions in the condensed consolidating financial statements for the six months ended September 30, 2016 and plans to revise the comparative presentation of the condensed consolidating financial statements for the period ended June 30, 2016 in future filings. Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 26,013 $ 171,791 $ 17,358 $ (145 ) $ 215,017 Other revenues — 72 33 494 (564 ) 35 Total revenues — 26,085 171,824 17,852 (709 ) 215,052 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 11,066 74,380 6,478 (837 ) 91,087 Gross profit — 15,019 97,444 11,374 128 123,965 Operating Expenses Advertising and promotion — 3,751 21,619 3,222 — 28,592 General and administrative 1,801 1,762 13,302 1,930 — 18,795 Depreciation and amortization 832 151 4,917 116 — 6,016 (Gain) loss on sale of assets — (496 ) — — (496 ) Total operating expenses 2,633 5,664 39,342 5,268 — 52,907 Operating income (loss) (2,633 ) 9,355 58,102 6,106 128 71,058 Other (income) expense Interest income (12,077 ) (21,459 ) (1,292 ) (156 ) 34,938 (46 ) Interest expense 8,502 20,882 25,138 1,292 (34,938 ) 20,876 Equity in (income) loss of subsidiaries (32,028 ) (27,020 ) (3,601 ) — 62,649 — Total other expense (income) (35,603 ) (27,597 ) 20,245 1,136 62,649 20,830 Income (loss) before income taxes 32,970 36,952 37,857 4,970 (62,521 ) 50,228 Provision for income taxes 775 3,526 12,363 1,369 — 18,033 Net income (loss) $ 32,195 $ 33,426 $ 25,494 $ 3,601 $ (62,521 ) $ 32,195 Comprehensive (loss) income, net of tax: Currency translation adjustments 2,703 2,703 2,703 2,703 (8,109 ) 2,703 Total other comprehensive (loss) income 2,703 2,703 2,703 2,703 (8,109 ) 2,703 Comprehensive (loss) income $ 34,898 $ 36,129 $ 28,197 $ 6,304 $ (70,630 ) $ 34,898 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 53,972 $ 339,996 $ 31,184 $ (1,365 ) $ 423,787 Other revenues — 147 834 980 (1,121 ) 840 Total revenues — 54,119 340,830 32,164 (2,486 ) 424,627 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 23,152 145,842 12,478 (2,401 ) 179,071 Gross profit — 30,967 194,988 19,686 (85 ) 245,556 Operating Expenses Advertising and promotion — 8,496 42,423 5,308 — 56,227 General and administrative 3,738 3,950 27,616 2,948 — 38,252 Depreciation and amortization 1,752 302 10,550 244 — 12,848 Loss on sale of assets — 54,957 — — 54,957 Total operating expenses 5,490 12,748 135,546 8,500 — 162,284 Operating income (loss) (5,490 ) 18,219 59,442 11,186 (85 ) 83,272 Other (income) expense Interest income (24,044 ) (42,721 ) (2,566 ) (315 ) 69,543 (103 ) Interest expense 16,942 42,056 50,039 2,566 (69,543 ) 42,060 Equity in (income) loss of subsidiaries (26,290 ) (13,761 ) (6,677 ) — 46,728 — Total other expense (income) (33,392 ) (14,426 ) 40,796 2,251 46,728 41,957 Income (loss) before income taxes 27,902 32,645 18,646 8,935 (46,813 ) 41,315 Provision for income taxes 1,238 6,704 4,451 2,258 — 14,651 Net income (loss) $ 26,664 $ 25,941 $ 14,195 $ 6,677 $ (46,813 ) $ 26,664 Comprehensive (loss) income, net of tax: Currency translation adjustments (3,121 ) (3,121 ) (3,121 ) (3,121 ) 9,363 (3,121 ) Total other comprehensive (loss) income (3,121 ) (3,121 ) (3,121 ) (3,121 ) 9,363 (3,121 ) Comprehensive (loss) income $ 23,543 $ 22,820 $ 11,074 $ 3,556 $ (37,450 ) $ 23,543 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,957 $ 164,772 $ 14,005 $ (1,472 ) $ 205,262 Other revenues — 79 798 543 (617 ) 803 Total revenues — 28,036 165,570 14,548 (2,089 ) 206,065 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,868 72,120 4,952 (1,815 ) 86,125 Gross profit — 17,168 93,450 9,596 (274 ) 119,940 Operating Expenses Advertising and promotion — 3,204 21,933 2,756 — 27,893 General and administrative 1,199 1,300 12,912 1,051 — 16,462 Depreciation and amortization 1,030 147 4,447 63 — 5,687 Total operating expenses 2,229 4,651 39,292 3,870 — 50,042 Operating income (loss) (2,229 ) 12,517 54,158 5,726 (274 ) 69,898 Other (income) expense Interest income (12,161 ) (21,607 ) (1,169 ) (126 ) 35,030 (33 ) Interest expense 8,964 20,303 25,294 1,169 (35,030 ) 20,700 Equity in (income) loss of subsidiaries (31,441 ) (19,746 ) (3,385 ) — 54,572 — Total other (income) expense (34,638 ) (21,050 ) 20,740 1,043 54,572 20,667 Income (loss) before income taxes 32,409 33,567 33,418 4,683 (54,846 ) 49,231 Provision for income taxes 606 4,892 10,632 1,298 — 17,428 Net income (loss) $ 31,803 $ 28,675 $ 22,786 $ 3,385 $ (54,846 ) $ 31,803 Comprehensive (loss) income, net of tax: Currency translation adjustments (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Total other comprehensive (loss) income (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Comprehensive income (loss) $ 20,724 $ 17,596 $ 11,707 $ (7,694 ) $ (21,609 ) $ 20,724 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 55,840 $ 317,296 $ 25,613 $ (2,200 ) $ 396,549 Other revenues — 175 1,617 1,041 (1,185 ) 1,648 Total revenues — 56,015 318,913 26,654 (3,385 ) 398,197 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 21,309 138,498 9,360 (3,146 ) 166,021 Gross profit — 34,706 180,415 17,294 (239 ) 232,176 Operating Expenses Advertising and promotion — 5,721 43,161 5,433 — 54,315 General and administrative 2,514 3,855 24,863 2,819 — 34,051 Depreciation and amortization 2,019 293 8,892 203 — 11,407 Total operating expenses 4,533 9,869 76,916 8,455 — 99,773 Operating income (loss) (4,533 ) 24,837 103,499 8,839 (239 ) 132,403 Other (income) expense Interest income (24,210 ) (43,015 ) (2,389 ) (238 ) 69,792 (60 ) Interest expense 17,454 42,211 50,349 2,389 (69,792 ) 42,611 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Total other (income) expense (63,503 ) (37,054 ) 43,125 2,151 98,283 43,002 Income (loss) before income taxes 58,970 61,891 60,374 6,688 (98,522 ) 89,401 Provision for income taxes 994 8,917 19,661 1,853 — 31,425 Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Comprehensive (loss) income, net of tax: Currency translation adjustments (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Total other comprehensive (loss) income (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Comprehensive income (loss) $ 46,492 $ 41,490 $ 29,229 $ (6,649 ) $ (64,070 ) $ 46,492 Condensed Consolidating Balance Sheet September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 8,168 $ — $ 292 $ 21,998 $ — $ 30,458 Accounts receivable, net — 11,677 67,356 13,836 — 92,869 Inventories — 12,910 75,088 10,578 (617 ) 97,959 Deferred income tax assets 297 807 8,652 890 — 10,646 Prepaid expenses and other current assets 2,189 546 7,926 680 — 11,341 Assets held for sale — — 36,400 — — 36,400 Total current assets 10,654 25,940 195,714 47,982 (617 ) 279,673 Property and equipment, net 7,963 314 4,889 566 — 13,732 Goodwill — 66,007 263,183 22,472 — 351,662 Intangible assets, net — 191,521 1,901,899 87,708 — 2,181,128 Other long-term assets 2,500 2,283 — — — 4,783 Intercompany receivables 1,478,481 2,573,184 1,461,115 12,506 (5,525,286 ) — Investment in subsidiary 1,665,764 1,538,358 83,983 — (3,288,105 ) — Total Assets $ 3,165,362 $ 4,397,607 $ 3,910,783 $ 171,234 $ (8,814,008 ) $ 2,830,978 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,643 $ 9,422 $ 24,097 $ 2,879 $ — $ 39,041 Accrued interest payable — 8,264 — — — 8,264 Other accrued liabilities 11,731 1,841 47,137 6,297 — 67,006 Total current liabilities 14,374 19,527 71,234 9,176 — 114,311 Long-term debt Principal amount — 1,502,000 — — — 1,502,000 Less unamortized debt costs — (22,337 ) — — — (22,337 ) Long-term debt, net — 1,479,663 — — — 1,479,663 Deferred income tax liabilities — 61,046 398,108 373 — 459,527 Other long-term liabilities — 2,682 155 — 2,837 Intercompany payables 2,376,348 1,246,668 1,821,773 80,497 (5,525,286 ) — Total Liabilities 2,390,722 2,806,904 2,293,797 90,201 (5,525,286 ) 2,056,338 Stockholders' Equity Common stock 532 — — — — 532 Additional paid-in capital 453,336 1,280,947 1,359,921 78,774 (2,719,642 ) 453,336 Treasury stock, at cost (6,558 ) — — — — (6,558 ) Accumulated other comprehensive (loss) income, net of tax (26,646 ) (26,646 ) (26,646 ) (26,646 ) 79,938 (26,646 ) Retained earnings (accumulated deficit) 353,976 336,402 283,711 28,905 (649,018 ) 353,976 Total Stockholders' Equity 774,640 1,590,703 1,616,986 81,033 (3,288,722 ) 774,640 Total Liabilities and Stockholders' Equity $ 3,165,362 $ 4,397,607 $ 3,910,783 $ 171,234 $ (8,814,008 ) $ 2,830,978 Condensed Consolidating Balance Sheet March 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 4,440 $ — $ 2,899 $ 19,891 $ — $ 27,230 Accounts receivable, net — 12,025 74,446 8,776 — 95,247 Inventories — 9,411 72,296 10,088 (532 ) 91,263 Deferred income tax assets 316 681 8,293 818 — 10,108 Prepaid expenses and other current assets 15,311 257 8,379 1,218 — 25,165 Total current assets 20,067 22,374 166,313 40,791 (532 ) 249,013 Property and equipment, net 9,166 210 5,528 636 — 15,540 Goodwill — 66,007 271,409 22,775 — 360,191 Intangible assets, net — 191,789 2,042,640 88,294 — 2,322,723 Other long-term assets — 1,324 — — — 1,324 Intercompany receivables 1,457,011 2,703,192 1,083,488 10,738 (5,254,429 ) — Investment in subsidiary 1,641,477 1,527,718 81,545 — (3,250,740 ) — Total Assets $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,914 $ 7,643 $ 24,437 $ 3,302 $ — $ 38,296 Accrued interest payable — 8,664 — — — 8,664 Other accrued liabilities 12,285 1,714 38,734 6,991 — 59,724 Total current liabilities 15,199 18,021 63,171 10,293 — 106,684 Long-term debt Principal amount — 1,652,500 — — — 1,652,500 Less unamortized debt costs — (27,191 ) — — — (27,191 ) Long-term debt, net — 1,625,309 — — — 1,625,309 Deferred income tax liabilities — 60,317 408,893 412 — 469,622 Other long-term liabilities — — 2,682 158 — 2,840 Intercompany payables 2,368,186 1,241,084 1,570,265 74,894 (5,254,429 ) — Total Liabilities 2,383,385 2,944,731 2,045,011 85,757 (5,254,429 ) 2,204,455 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 445,182 1,280,947 1,359,921 78,774 (2,719,642 ) 445,182 Treasury stock, at cost (5,163 ) — — — — (5,163 ) Accumulated other comprehensive income (loss), net of tax (23,525 ) (23,525 ) (23,525 ) (23,525 ) 70,575 (23,525 ) Retained earnings (accumulated deficit) 327,312 310,461 269,516 22,228 (602,205 ) 327,312 Total Stockholders' Equity 744,336 1,567,883 1,605,912 77,477 (3,251,272 ) 744,336 Total Liabilities and Stockholders' Equity $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791 Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 26,664 $ 25,941 $ 14,195 $ 6,677 $ (46,813 ) $ 26,664 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 1,752 302 10,550 244 — 12,848 Loss on sales of intangible assets and property and equipment — 55,112 — — 55,112 Deferred income taxes 19 603 (11,144 ) (80 ) — (10,602 ) Amortization of debt origination costs — 5,097 — — — 5,097 Stock-based compensation costs 3,933 — — — — 3,933 Equity in income of subsidiaries (26,290 ) (13,761 ) (6,677 ) — 46,728 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 348 7,090 (7,082 ) — 356 Inventories — (3,499 ) (6,596 ) (653 ) 85 (10,663 ) Prepaid expenses and other current assets 10,622 (289 ) (735 ) 514 — 10,112 Accounts payable (297 ) 1,779 (164 ) (498 ) — 820 Accrued liabilities (554 ) (273 ) 8,284 (852 ) — 6,605 Net cash provided by (used in) operating activities 15,849 16,248 69,915 (1,730 ) — 100,282 Investing Activities Purchases of property and equipment (395 ) (138 ) (785 ) (86 ) — (1,404 ) Proceeds from sales of intangible assets — — 52,353 — — 52,353 Proceeds from the sale of property and equipment — — 75 — — 75 Net cash provided by (used in) investing activities (395 ) (138 ) 51,643 (86 ) — 51,024 Financing Activities Term loan repayments — (130,500 ) — — — (130,500 ) Borrowings under revolving credit agreement — 20,000 — — — 20,000 Repayments under revolving credit agreement — (40,000 ) — — — (40,000 ) Payments of debt origination costs — (9 ) — — — (9 ) Proceeds from exercise of stock options 3,423 — — — — 3,423 Excess tax benefits from share-based awards 800 — — — — 800 Fair value of shares surrendered as payment of tax withholding (1,395 ) — — — — (1,395 ) Intercompany activity, net (14,554 ) 134,399 (124,165 ) 4,320 — — Net cash (used in) provided by financing activities (11,726 ) (16,110 ) (124,165 ) 4,320 — (147,681 ) Effect of exchange rate changes on cash and cash equivalents — — — (397 ) — (397 ) Increase (decrease) in cash and cash equivalents 3,728 — (2,607 ) 2,107 — 3,228 Cash and cash equivalents - beginning of period 4,440 — 2,899 19,891 — 27,230 Cash and cash equivalents - end of period $ 8,168 $ — $ 292 $ 21,998 $ — $ 30,458 Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 2,019 293 8,892 203 — 11,407 Gain on sale of property and equipment — — — (36 ) — (36 ) Deferred income taxes 171 254 21,506 54 — 21,985 Amortization of debt origination costs — 4,055 — — — 4,055 Stock-based compensation costs 4,993 — — 41 — 5,034 Loss on extinguishment of debt — 451 — — — 451 Equity in income of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,729 (3,550 ) (2,097 ) — (3,918 ) Inventories — (1,017 ) (2,177 ) (883 ) 239 (3,838 ) Prepaid expenses and other current assets 3,166 (402 ) 660 12 — 3,436 Accounts payable 269 624 (3,343 ) (2,069 ) — (4,519 ) Accrued liabilities (2,503 ) (1,094 ) 1,012 1,142 — (1,443 ) Net cash provided by operating activities 9,344 21,166 58,878 1,202 — 90,590 Investing Activities Purchases of property and equipment (1,107 ) (93 ) (103 ) (380 ) — (1,683 ) Proceeds from the sale of property and equipment — — — 344 — 344 Net cash used in investing activities (1,107 ) (93 ) (103 ) (36 ) — (1,339 ) Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (55,000 ) — — — (55,000 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,398 — — — — 6,398 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net (15,675 ) 73,138 (58,775 ) 1,312 — — Net cash (used in) provided by financing activities (9,070 ) (21,073 ) (58,775 ) 1,312 — (87,606 ) Effect of exchange rate changes on cash and cash equivalents — — — (811 ) — (811 ) Increase (decrease) in cash and cash equivalents (833 ) — — 1,667 — 834 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 10,554 $ — $ — $ 11,598 $ — $ 22,152

Business and Basis of Present26

Business and Basis of Presentation (Policies)	6 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The unaudited Consolidated Financial Statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated in these Consolidated Financial Statements. In the opinion of management, these Consolidated Financial Statements include all adjustments, consisting of normal recurring adjustments, that are considered necessary for a fair statement of our consolidated financial position, results of operations and cash flows for the interim periods presented. Our fiscal year ends on March 31 st of each year. References in these Consolidated Financial Statements or related notes to a year (e.g., “2017”) mean our fiscal year ending or ended on March 31 st of that year. Operating results for the three and six months ended September 30, 2016 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2017 . These unaudited Consolidated Financial Statements and related notes should be read in conjunction with our audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2016 .
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on our knowledge of current events and actions that we may undertake in the future, actual results could differ from those estimates. As discussed below, our most significant estimates include those made in connection with the valuation of intangible assets, stock-based compensation, fair value of debt, sales returns and allowances, trade promotional allowances and inventory obsolescence, and the recognition of income taxes using an estimated annual effective tax rate.
Cash and Cash Equivalents	Cash and Cash Equivalents We consider all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of our cash is held by a large regional bank with headquarters in California. We do not believe that, as a result of this concentration, we are subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships. The Federal Deposit Insurance Corporation (“FDIC”) and Securities Investor Protection Corporation (“SIPC”) insure these balances up to $250,000 and $500,000, with a $250,000 limit for cash, respectively. Substantially all of the Company's cash balances at September 30, 2016 are uninsured, and approximately 27.8% of our consolidated cash balances at September 30, 2016 are located in the United States.
Accounts Receivable	Accounts Receivable We extend non-interest-bearing trade credit to our customers in the ordinary course of business. We maintain an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, we (i) have established credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of customers' financial condition, (iii) monitor the payment history and aging of customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.
Inventories	Inventories Inventories are stated at the lower of cost or market value, with cost determined by using the first-in, first-out method. We reduce inventories for diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include: (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, we remove the cost and associated accumulated depreciation from the respective accounts and recognize the resulting gain or loss in the Consolidated Statements of Income and Comprehensive Income. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Goodwill	Goodwill The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business combinations is classified as goodwill. Goodwill is not amortized, although the carrying value is tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Goodwill is tested for impairment at the product group level, which is one level below the operating segment level.
Intangible Assets	Intangible Assets Intangible assets, which are comprised primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed using the straight-line method over estimated useful lives, typically ranging from 10 to 30 years. Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter of each year, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts may exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.
Debt Origination Costs	Debt Origination Costs We have incurred debt origination costs in connection with the issuance of our long-term debt. These costs are amortized over the term of the related debt, using the effective interest method for our bonds and our term loan facility and the straight-line method for our revolving credit facility.
Revenue Recognition	Revenue Recognition Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the selling price is fixed or determinable, (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss, and (iv) collection of the resulting receivable is reasonably assured. We have determined that these criteria are met and the transfer of the risk of loss generally occurs when the product is received by the customer, and, accordingly, we recognize revenue at that time. Provisions are made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience. As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs varies based on the actual number of units sold during a finite period of time. These promotional programs consist of direct-to-consumer incentives, such as coupons and temporary price reductions, as well as incentives to our customers, such as allowances for new distribution, including slotting fees, and cooperative advertising. Estimates of the costs of these promotional programs are based on (i) historical sales experience, (ii) the current promotional offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. We recognize the cost of such sales incentives by recording an estimate of such cost as a reduction of revenue, at the later of (a) the date the related revenue is recognized, or (b) the date when a particular sales incentive is offered. At the completion of a promotional program, the estimated amounts are adjusted to actual results. Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with recording sales, which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.
Cost of Sales	Cost of Sales Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs.
Advertising and Promotion Costs	Advertising and Promotion Costs Advertising and promotion costs are expensed as incurred. Allowances for distribution costs associated with products, including slotting fees, are recognized as a reduction of sales. Under these new distribution arrangements, the retailers allow our products to be placed on the stores' shelves in exchange for such fees.
Stock-based Compensation	Stock-based Compensation We recognize stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is recognized over the period a grantee is required to provide service in exchange for the award, generally referred to as the requisite service period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Income Taxes topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740 prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities. As a result, we have applied such guidance in determining our tax uncertainties. We are subject to taxation in the United States and various state and foreign jurisdictions. We classify penalties and interest related to unrecognized tax benefits as income tax expense in the Consolidated Statements of Income and Comprehensive Income.
Earnings Per Share	Earnings Per Share Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of outstanding stock options and unvested restricted stock units, are included in the earnings per share calculation to the extent that they are dilutive. In loss periods, the assumed exercise of in-the-money stock options and restricted stock units has an anti-dilutive effect, and therefore these instruments are excluded from the computation of diluted earnings per share.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In August 2016, the FASB issued Accounting Standards Update ("ASU") 2016-15, Classification of Certain Cash Receipts and Cash Payments . The amendments in this update provide clarification and guidance on eight cash flow classification issues. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The adoption of ASU 2016-15 is not expected to have a material impact on our Consolidated Financial Statements. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers . The amendments do not change the core principle of the guidance in FASB ASC 606, discussed below. Rather, the amendments in this update affect only certain narrow aspects of FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on identifying performance obligations and licensing in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting . The amendments in this update involve several aspects of accounting for share-based payment transactions, including income tax consequences, classification of awards, and classification on the statement of cash flows. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers . The amendments in this update clarify the implementation guidance on principals versus agent considerations in FASB ASC 606. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements of ASU 2014-09 described below. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In February 2016, the FASB issued ASU 2016-02, Leases. The amendments in this update include a new FASB ASC Topic 842, which supersedes Topic 840. The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. For public business entities, the amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes . The amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this update may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. For public business entities, the amendments in this update are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Early application is permitted for all entities as of the beginning of interim or annual reporting periods. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements. In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The amendments in this update more closely align the measurement of inventory in GAAP with the measurement of inventory in International Financial Reporting Standards, under which an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. For public business entities, the amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The adoption of ASU 2015-11 is not expected to have a material impact on our Consolidated Financial Statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers - Topic 606 , which supersedes the revenue recognition requirements in FASB ASC 605. The new guidance primarily states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In August 2015, the FASB issued ASU 2015-14, which deferred the effective date of ASU 2014-09 from annual and interim periods beginning after December 15, 2016 to annual and interim periods beginning after December 15, 2017. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. We are evaluating the impact of adopting this guidance on our Consolidated Financial Statements.

Business and Basis of Present27

Business and Basis of Presentation (Tables)	6 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) September 30, March 31, Components of Property and Equipment Machinery $ 8,122 $ 7,734 Computer equipment 12,928 12,793 Furniture and fixtures 2,501 2,445 Leasehold improvements 7,372 7,389 30,923 30,361 Accumulated depreciation (17,191 ) (14,821 ) Property and equipment, net $ 13,732 $ 15,540

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Allocation of Assets Acquired and Liabilities Assumed	The following table summarizes our preliminary allocation of the assets acquired and liabilities assumed as of the February 5, 2016 acquisition date. (In thousands) February 5, 2016 Cash acquired $ 1,359 Accounts receivable 9,187 Inventories 14,304 Deferred income taxes 3,303 Prepaids and other current assets 6,728 Property, plant and equipment, net 3,555 Goodwill 76,529 Intangible assets, net 206,700 Total assets acquired 321,665 Accounts payable 3,261 Accrued expenses 16,488 Deferred income tax liabilities - long term 73,573 Total liabilities assumed 93,322 Total purchase price $ 228,343

Divestitures and Assets Held 29

Divestitures and Assets Held For Sale (Tables)	6 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Divestitures	The following table sets forth the components of the assets sold and the pre-tax loss recognized on the sale. (In thousands) July 7, Components of assets sold: Inventory $ 2,380 Intangible assets, net 91,208 Goodwill 2,920 Assets sold 96,508 Total purchase price to be received 42,380 54,128 Costs to sell 2,018 Pre-tax loss on sale $ 56,146 As such, we expect to conclude this transaction by March 31, 2017 and the following table sets forth the assets held for sale as of September 30, 2016 related to our Dermoplast brand. (In thousands) September 30, Components of assets held for sale: Inventory $ 619 Intangible assets, net 31,030 Goodwill 4,751 Assets Held for Sale $ 36,400

Accounts Receivable (Tables)

Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Accounts Receivable	Accounts receivable consist of the following: (In thousands) September 30, March 31, Components of Accounts Receivable Trade accounts receivable $ 103,744 $ 105,592 Other receivables 1,011 1,261 104,755 106,853 Less allowances for discounts, returns and uncollectible accounts (11,886 ) (11,606 ) Accounts receivable, net $ 92,869 $ 95,247

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories consist of the following: (In thousands) September 30, March 31, Components of Inventories Packaging and raw materials $ 7,552 $ 7,563 Finished goods 90,407 83,700 Inventories $ 97,959 $ 91,263

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives: Years Machinery 5 Computer equipment and software 3 Furniture and fixtures 7 Leasehold improvements * *Leasehold improvements are amortized over the lesser of the term of the lease or the estimated useful life of the related asset. Property and equipment consist of the following: (In thousands) September 30, March 31, Components of Property and Equipment Machinery $ 8,122 $ 7,734 Computer equipment 12,928 12,793 Furniture and fixtures 2,501 2,445 Leasehold improvements 7,372 7,389 30,923 30,361 Accumulated depreciation (17,191 ) (14,821 ) Property and equipment, net $ 13,732 $ 15,540

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Goodwill	A reconciliation of the activity affecting goodwill by operating segment is as follows: (In thousands) North American OTC Healthcare International OTC Healthcare Household Cleaning Consolidated Balance — March 31, 2016 $ 330,615 $ 22,776 $ 6,800 $ 360,191 Reductions (7,670 ) — (555 ) (8,225 ) Effects of foreign currency exchange rates — (304 ) — (304 ) Balance — September 30, 2016 $ 322,945 $ 22,472 $ 6,245 $ 351,662

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Reconciliation of the Activity Affecting Intangible Assets	A reconciliation of the activity affecting intangible assets is as follows: (In thousands) Indefinite Lived Trademarks Finite Lived Totals Gross Carrying Amounts Balance — March 31, 2016 $ 2,020,046 $ 417,880 $ 2,437,926 Reductions (77,248 ) (60,103 ) (137,351 ) Effects of foreign currency exchange rates (380 ) (103 ) (483 ) Balance — September 30, 2016 1,942,418 357,674 2,300,092 Accumulated Amortization Balance — March 31, 2016 — 115,203 115,203 Additions — 9,865 9,865 Reductions — (6,102 ) (6,102 ) Effects of foreign currency exchange rates — (2 ) (2 ) Balance — September 30, 2016 — 118,964 118,964 Intangible assets, net - September 30, 2016 $ 1,942,418 $ 238,710 $ 2,181,128 Intangible Assets, net by Reportable Segment: North American OTC Healthcare $ 1,755,636 $ 215,817 $ 1,971,453 International OTC Healthcare 85,520 1,087 86,607 Household Cleaning 101,262 21,806 123,068 Intangible assets, net - September 30, 2016 $ 1,942,418 $ 238,710 $ 2,181,128
Schedule of Expected Amortization Expense	At September 30, 2016 , finite-lived intangible assets are being amortized over a period of 10 to 30 years, and the associated amortization expense is expected to be as follows: (In thousands) Year Ending March 31, Amount 2017 (Remaining six months ending March 31, 2017) $ 9,113 2018 18,062 2019 18,062 2020 18,062 2021 17,640 Thereafter 157,771 $ 238,710

Other Accrued Liabilities (Tabl

Other Accrued Liabilities (Tables)	6 Months Ended
	Sep. 30, 2016
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following: (In thousands) September 30, March 31, Accrued marketing costs $ 29,938 $ 26,373 Accrued compensation costs 5,572 9,574 Accrued broker commissions 965 1,497 Income taxes payable 10,284 3,675 Accrued professional fees 3,050 1,787 Deferred rent 690 836 Accrued production costs 3,023 3,324 Accrued lease termination costs 384 448 Income tax related payable 6,354 6,354 Other accrued liabilities 6,746 5,856 $ 67,006 $ 59,724

Long-Term Debt (Tables)

Long-Term Debt (Tables)	6 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following, as of the dates indicated: (In thousands, except percentages) September 30, March 31, 2016 Senior Notes bearing interest at 6.375%, with interest payable on March 1 and September 1 of each year. The 2016 Senior Notes mature on March 1, 2024. $ 350,000 $ 350,000 2013 Senior Notes bearing interest at 5.375%, with interest payable on June 15 and December 15 of each year. The 2013 Senior Notes mature on December 15, 2021. 400,000 400,000 2012 Term B-3 Loans bearing interest at the Borrower's option at either a base rate with a floor of 1.75% plus applicable margin or LIBOR with a floor of 0.75% plus applicable margin, due on September 3, 2021. 687,000 817,500 2012 ABL Revolver bearing interest at the Borrower's option at either a base rate plus applicable margin or LIBOR plus applicable margin. Any unpaid balance is due on June 9, 2020. 65,000 85,000 Total long-term debt (including current portion) 1,502,000 1,652,500 Current portion of long-term debt — — Long-term debt 1,502,000 1,652,500 Less: unamortized debt costs (22,337 ) (27,191 ) Long-term debt, net $ 1,479,663 $ 1,625,309
Aggregate Future Principal Payments	At September 30, 2016, aggregate future principal payments required in accordance with the terms of the 2012 Term Loan, 2012 ABL Revolver and the indentures governing the 2016 Senior Notes and the 2013 Senior Notes are as follows: (In thousands) Year Ending March 31, Amount 2017 (remaining six months ending March 31, 2017) $ — 2018 — 2019 — 2020 — 2021 65,000 Thereafter 1,437,000 $ 1,502,000

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Summary of Carry Amounts and Fair Value Measurements	As such, the 2016 Senior Notes, the 2013 Senior Notes, the Term B-3 Loans, and the 2012 ABL Revolver are measured in Level 2 of the above hierarchy (see summary below detailing the carrying amounts and estimated fair values of these borrowings at September 30, 2016 and March 31, 2016). September 30, 2016 March 31, 2016 (In thousands) Carrying Value Fair Value Carrying Value Fair Value 2016 Senior Notes $ 350,000 $ 371,000 $ 350,000 $ 363,125 2013 Senior Notes 400,000 414,000 400,000 408,000 Term B-3 Loans 687,000 693,011 817,500 818,522 2012 ABL Revolver 65,000 65,000 85,000 85,000

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income	The table below presents accumulated other comprehensive loss (“AOCI”), which affects equity and results from recognized transactions and other economic events, other than transactions with owners in their capacity as owners. AOCI consisted of the following at September 30, 2016 and March 31, 2016 : September 30, March 31, (In thousands) 2016 2016 Components of Accumulated Other Comprehensive Loss Cumulative translation adjustment $ (26,646 ) $ (23,525 ) Accumulated other comprehensive loss, net of tax $ (26,646 ) $ (23,525 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The following table sets forth the computation of basic and diluted earnings per share: Three Months Ended September 30, Six Months Ended September 30, (In thousands, except per share data) 2016 2015 2016 2015 Numerator Net income $ 32,195 $ 31,803 $ 26,664 $ 57,976 Denominator Denominator for basic earnings per share — weighted average shares outstanding 52,993 52,803 52,941 52,676 Dilutive effect of unvested restricted stock units and options issued to employees and directors 352 348 388 379 Denominator for diluted earnings per share 53,345 53,151 53,329 53,055 Earnings per Common Share: Basic net earnings per share $ 0.61 $ 0.60 $ 0.50 $ 1.10 Diluted net earnings per share $ 0.60 $ 0.60 $ 0.50 $ 1.09

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Restricted Shares	A summary of the Company's restricted stock units granted under the Plan is presented below: Restricted Stock Units Shares (in thousands) Weighted- Average Grant-Date Fair Value Six months ended September 30, 2015 Vested and nonvested at March 31, 2015 362.3 $ 22.74 Granted 259.5 42.20 Vested and issued (153.6 ) 18.16 Forfeited (1.4 ) 33.50 Vested and nonvested at September 30, 2015 466.8 35.03 Vested at September 30, 2015 69.8 14.76 Six months ended September 30, 2016 Vested and nonvested at March 31, 2016 467.8 $ 35.22 Granted 65.8 55.65 Vested and issued (92.7 ) 28.47 Forfeited (91.0 ) 41.69 Vested and nonvested at September 30, 2016 349.9 39.16 Vested at September 30, 2016 63.4 20.12
Fair Value of Options Granted	Six months ended September 30, 2016 2015 Expected volatility 37.8 % 40.2 % Expected dividends $ — $ — Expected term in years 6.0 6.0 Risk-free rate 1.7 % 1.7 %
Stock Option Activity	A summary of option activity under the Plan is as follows: Options Shares (in thousands) Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands) Six months ended September 30, 2015 Outstanding at March 31, 2015 871.2 $ 23.40 Granted 200.1 41.80 Exercised (336.9 ) 18.99 Forfeited or expired (2.1 ) 38.16 Outstanding at September 30, 2015 732.3 30.42 8.1 $ 10,816 Exercisable at September 30, 2015 319.5 21.91 7.0 $ 7,430 Six months ended September 30, 2016 Outstanding at March 31, 2016 727.7 $ 30.70 Granted 250.6 56.17 Exercised (107.1 ) 31.97 Forfeited or expired (90.7 ) 42.56 Outstanding at September 30, 2016 780.5 37.33 7.5 $ 10,326 Exercisable at September 30, 2016 383.7 25.61 6.5 $ 8,693

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The following summarizes future minimum lease payments for our operating leases as of September 30, 2016 : (In thousands) Year Ending March 31, Facilities Equipment Total (a) 2017 (Remaining six months ending March 31, 2017) $ 1,048 $ 76 $ 1,124 2018 2,029 152 2,181 2019 2,023 152 2,175 2020 1,848 89 1,937 2021 903 — 903 Thereafter 59 — 59 $ 7,910 $ 469 $ 8,379 (a) Minimum lease payments have not been reduced by minimum sublease rentals of $1.0 million due to us in the future under noncancelable subleases. The following schedule shows the composition of total minimum lease payments that have been reduced by minimum sublease rentals: (In thousands) September 30, 2016 March 31, 2016 Minimum lease payments $ 8,379 $ 8,434 Less: Sublease rentals (1,036 ) (1,165 ) $ 7,343 $ 7,269
Purchase Commitments Minimum Amounts Set Forth	Although we are committed under the supply agreement to pay the minimum amounts set forth in the table below, the total commitment is less than 10% of the estimated purchases that we expect to make during the course of the agreement. (In thousands) Year Ending March 31, Amount 2017 (Remaining six months ending March 31, 2017) 518 2018 1,013 2019 982 2020 559 2021 — $ 3,072

Business Segments (Tables)

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Information about our Operating and Reportable Segments	The tables below summarize information about our reportable segments. Three Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 172,590 $ 18,802 $ 23,768 $ 215,160 Elimination of intersegment revenues (143 ) — — (143 ) Third-party segment revenues 172,447 18,802 23,768 215,017 Other revenues — 2 33 35 Total segment revenues 172,447 18,804 23,801 215,052 Cost of sales 65,402 7,096 18,589 91,087 Gross profit 107,045 11,708 5,212 123,965 Advertising and promotion 24,811 3,244 537 28,592 Contribution margin $ 82,234 $ 8,464 $ 4,675 95,373 Other operating expenses* 24,315 Operating income 71,058 Other expense 20,830 Income before income taxes 50,228 Provision for income taxes 18,033 Net income $ 32,195 *Other operating expenses for the three months ended September 30, 2016 includes a pre-tax loss on sale of assets of $0.7 million related to Pediacare , New Skin, and Fiber Choice and a pre-tax gain on sale of assets of $1.2 million associated with the sale of license rights in certain geographic areas pertaining to Comet . The assets and corresponding contribution margin associated with the pre-tax loss on sale of assets related to Pediacare , New Skin, and Fiber Choice are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment. Six Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues $ 345,891 $ 34,602 $ 44,658 $ 425,151 Elimination of intersegment revenues (1,364 ) — — (1,364 ) Third-party segment revenues 344,527 34,602 44,658 423,787 Other revenues — 6 834 840 Total segment revenues 344,527 34,608 45,492 424,627 Cost of sales 129,636 14,044 35,391 179,071 Gross profit 214,891 20,564 10,101 245,556 Advertising and promotion 49,851 5,368 1,008 56,227 Contribution margin $ 165,040 $ 15,196 $ 9,093 189,329 Other operating expenses* 106,057 Operating income 83,272 Other expense 41,957 Income before income taxes 41,315 Provision for income taxes 14,651 Net income $ 26,664 *Other operating expenses for the six months ended September 30, 2016 includes a pre-tax loss on sale of assets of $56.2 million related to Pediacare , New Skin, and Fiber Choice and a pre-tax gain on sale of assets of $1.2 million associated with the sale of license rights in certain geographic areas pertaining to Comet . The assets and corresponding contribution margin associated with the pre-tax loss on sale of assets related to Pediacare , New Skin, and Fiber Choice are included within the North American OTC Healthcare segment, while the pre-tax gain on sale of license rights related to Comet are included in the Household Cleaning segment. Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 166,886 $ 15,954 $ 23,894 $ 206,734 Elimination of intersegment revenues (1,472 ) — — (1,472 ) Third-party segment revenues 165,414 15,954 23,894 205,262 Other revenues** — 6 797 803 Total segment revenues 165,414 15,960 24,691 206,065 Cost of sales** 61,497 6,094 18,534 86,125 Gross profit 103,917 9,866 6,157 119,940 Advertising and promotion 24,440 2,777 676 27,893 Contribution margin $ 79,477 $ 7,089 $ 5,481 92,047 Other operating expenses 22,149 Operating income 69,898 Other expense 20,667 Income before income taxes 49,231 Provision for income taxes 17,428 Net income $ 31,803 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Cleaning Consolidated Gross segment revenues** $ 323,978 $ 29,410 $ 45,361 $ 398,749 Elimination of intersegment revenues (2,200 ) — — (2,200 ) Third-party segment revenues 321,778 29,410 45,361 396,549 Other revenues** 15 31 1,602 1,648 Total segment revenues 321,793 29,441 46,963 398,197 Cost of sales** 119,624 11,383 35,014 166,021 Gross profit 202,169 18,058 11,949 232,176 Advertising and promotion 47,635 5,500 1,180 54,315 Contribution margin $ 154,534 $ 12,558 $ 10,769 177,861 Other operating expenses 45,458 Operating income 132,403 Other expense 43,002 Income before income taxes 89,401 Provision for income taxes 31,425 Net income $ 57,976 ** Certain immaterial amounts relating to gross segment revenues, other revenues and cost of sales for each of the three and six months ended September 30, 2015 were reclassified between the International OTC Healthcare segment and the North American OTC Healthcare segment. There were no changes to the consolidated financial statements for any periods presented.
Information about our Revenues from Similar Product Groups	The tables below summarize information about our segment revenues from similar product groups. Three Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,993 $ 544 $ — $ 30,537 Cough & Cold 21,106 5,160 — 26,266 Women's Health 33,268 635 — 33,903 Gastrointestinal 16,280 6,088 — 22,368 Eye & Ear Care 22,934 2,989 — 25,923 Dermatologicals 22,952 567 — 23,519 Oral Care 24,368 2,820 — 27,188 Other OTC 1,546 1 — 1,547 Household Cleaning — — 23,801 23,801 Total segment revenues $ 172,447 $ 18,804 $ 23,801 $ 215,052 Six Months Ended September 30, 2016 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 58,119 $ 1,071 $ — $ 59,190 Cough & Cold 39,073 9,552 — 48,625 Women's Health 66,155 1,571 — 67,726 Gastrointestinal 35,386 10,344 — 45,730 Eye & Ear Care 48,941 5,785 — 54,726 Dermatologicals 45,650 1,238 — 46,888 Oral Care 48,179 5,037 — 53,216 Other OTC 3,024 10 — 3,034 Household Cleaning — — 45,492 45,492 Total segment revenues $ 344,527 $ 34,608 $ 45,492 $ 424,627 Three Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 29,694 $ 688 $ — $ 30,382 Cough & Cold 24,456 4,746 — 29,202 Women's Health 33,607 804 — 34,411 Gastrointestinal 19,061 5,342 — 24,403 Eye & Ear Care 24,163 3,578 — 27,741 Dermatologicals 23,197 611 — 23,808 Oral Care 9,733 189 — 9,922 Other OTC 1,503 2 — 1,505 Household Cleaning — — 24,691 24,691 Total segment revenues $ 165,414 $ 15,960 $ 24,691 $ 206,065 Six Months Ended September 30, 2015 (In thousands) North American OTC International OTC Household Consolidated Analgesics $ 56,542 $ 1,218 $ — $ 57,760 Cough & Cold 44,215 9,252 — 53,467 Women's Health 66,515 1,504 — 68,019 Gastrointestinal 39,381 9,150 — 48,531 Eye & Ear Care 49,223 6,780 — 56,003 Dermatologicals 43,292 1,145 — 44,437 Oral Care 19,710 383 — 20,093 Other OTC 2,915 9 — 2,924 Household Cleaning — — 46,963 46,963 Total segment revenues $ 321,793 $ 29,441 $ 46,963 $ 398,197
Allocation of Long-Term Assets to Segments	These consolidated goodwill and intangible assets have been allocated to the reportable segments as follows: September 30, 2016 (In thousands) North American OTC International OTC Household Cleaning Consolidated Goodwill $ 322,945 $ 22,472 $ 6,245 $ 351,662 Intangible assets Indefinite-lived 1,755,636 85,520 101,262 1,942,418 Finite-lived 215,817 1,087 21,806 238,710 Intangible assets, net 1,971,453 86,607 123,068 2,181,128 Total $ 2,294,398 $ 109,079 $ 129,313 $ 2,532,790 March 31, 2016 (In thousands) North American OTC International OTC Household Consolidated Goodwill $ 330,615 $ 22,776 $ 6,800 $ 360,191 Intangible assets Indefinite-lived 1,823,873 85,901 110,272 2,020,046 Finite-lived 277,762 2,237 22,678 302,677 Intangible assets, net 2,101,635 88,138 132,950 2,322,723 Total $ 2,432,250 $ 110,914 $ 139,750 $ 2,682,914

Condensed Consolidating Finan43

Condensed Consolidating Financial Statements (Tables)	6 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Consolidating Statements of Income and Comprehensive Income	Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 26,013 $ 171,791 $ 17,358 $ (145 ) $ 215,017 Other revenues — 72 33 494 (564 ) 35 Total revenues — 26,085 171,824 17,852 (709 ) 215,052 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 11,066 74,380 6,478 (837 ) 91,087 Gross profit — 15,019 97,444 11,374 128 123,965 Operating Expenses Advertising and promotion — 3,751 21,619 3,222 — 28,592 General and administrative 1,801 1,762 13,302 1,930 — 18,795 Depreciation and amortization 832 151 4,917 116 — 6,016 (Gain) loss on sale of assets — (496 ) — — (496 ) Total operating expenses 2,633 5,664 39,342 5,268 — 52,907 Operating income (loss) (2,633 ) 9,355 58,102 6,106 128 71,058 Other (income) expense Interest income (12,077 ) (21,459 ) (1,292 ) (156 ) 34,938 (46 ) Interest expense 8,502 20,882 25,138 1,292 (34,938 ) 20,876 Equity in (income) loss of subsidiaries (32,028 ) (27,020 ) (3,601 ) — 62,649 — Total other expense (income) (35,603 ) (27,597 ) 20,245 1,136 62,649 20,830 Income (loss) before income taxes 32,970 36,952 37,857 4,970 (62,521 ) 50,228 Provision for income taxes 775 3,526 12,363 1,369 — 18,033 Net income (loss) $ 32,195 $ 33,426 $ 25,494 $ 3,601 $ (62,521 ) $ 32,195 Comprehensive (loss) income, net of tax: Currency translation adjustments 2,703 2,703 2,703 2,703 (8,109 ) 2,703 Total other comprehensive (loss) income 2,703 2,703 2,703 2,703 (8,109 ) 2,703 Comprehensive (loss) income $ 34,898 $ 36,129 $ 28,197 $ 6,304 $ (70,630 ) $ 34,898 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Brands, Inc., the issuer Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 53,972 $ 339,996 $ 31,184 $ (1,365 ) $ 423,787 Other revenues — 147 834 980 (1,121 ) 840 Total revenues — 54,119 340,830 32,164 (2,486 ) 424,627 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 23,152 145,842 12,478 (2,401 ) 179,071 Gross profit — 30,967 194,988 19,686 (85 ) 245,556 Operating Expenses Advertising and promotion — 8,496 42,423 5,308 — 56,227 General and administrative 3,738 3,950 27,616 2,948 — 38,252 Depreciation and amortization 1,752 302 10,550 244 — 12,848 Loss on sale of assets — 54,957 — — 54,957 Total operating expenses 5,490 12,748 135,546 8,500 — 162,284 Operating income (loss) (5,490 ) 18,219 59,442 11,186 (85 ) 83,272 Other (income) expense Interest income (24,044 ) (42,721 ) (2,566 ) (315 ) 69,543 (103 ) Interest expense 16,942 42,056 50,039 2,566 (69,543 ) 42,060 Equity in (income) loss of subsidiaries (26,290 ) (13,761 ) (6,677 ) — 46,728 — Total other expense (income) (33,392 ) (14,426 ) 40,796 2,251 46,728 41,957 Income (loss) before income taxes 27,902 32,645 18,646 8,935 (46,813 ) 41,315 Provision for income taxes 1,238 6,704 4,451 2,258 — 14,651 Net income (loss) $ 26,664 $ 25,941 $ 14,195 $ 6,677 $ (46,813 ) $ 26,664 Comprehensive (loss) income, net of tax: Currency translation adjustments (3,121 ) (3,121 ) (3,121 ) (3,121 ) 9,363 (3,121 ) Total other comprehensive (loss) income (3,121 ) (3,121 ) (3,121 ) (3,121 ) 9,363 (3,121 ) Comprehensive (loss) income $ 23,543 $ 22,820 $ 11,074 $ 3,556 $ (37,450 ) $ 23,543 Condensed Consolidating Statements of Income and Comprehensive Income Three Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 27,957 $ 164,772 $ 14,005 $ (1,472 ) $ 205,262 Other revenues — 79 798 543 (617 ) 803 Total revenues — 28,036 165,570 14,548 (2,089 ) 206,065 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 10,868 72,120 4,952 (1,815 ) 86,125 Gross profit — 17,168 93,450 9,596 (274 ) 119,940 Operating Expenses Advertising and promotion — 3,204 21,933 2,756 — 27,893 General and administrative 1,199 1,300 12,912 1,051 — 16,462 Depreciation and amortization 1,030 147 4,447 63 — 5,687 Total operating expenses 2,229 4,651 39,292 3,870 — 50,042 Operating income (loss) (2,229 ) 12,517 54,158 5,726 (274 ) 69,898 Other (income) expense Interest income (12,161 ) (21,607 ) (1,169 ) (126 ) 35,030 (33 ) Interest expense 8,964 20,303 25,294 1,169 (35,030 ) 20,700 Equity in (income) loss of subsidiaries (31,441 ) (19,746 ) (3,385 ) — 54,572 — Total other (income) expense (34,638 ) (21,050 ) 20,740 1,043 54,572 20,667 Income (loss) before income taxes 32,409 33,567 33,418 4,683 (54,846 ) 49,231 Provision for income taxes 606 4,892 10,632 1,298 — 17,428 Net income (loss) $ 31,803 $ 28,675 $ 22,786 $ 3,385 $ (54,846 ) $ 31,803 Comprehensive (loss) income, net of tax: Currency translation adjustments (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Total other comprehensive (loss) income (11,079 ) (11,079 ) (11,079 ) (11,079 ) 33,237 (11,079 ) Comprehensive income (loss) $ 20,724 $ 17,596 $ 11,707 $ (7,694 ) $ (21,609 ) $ 20,724 Condensed Consolidating Statements of Income and Comprehensive Income Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Revenues Net sales $ — $ 55,840 $ 317,296 $ 25,613 $ (2,200 ) $ 396,549 Other revenues — 175 1,617 1,041 (1,185 ) 1,648 Total revenues — 56,015 318,913 26,654 (3,385 ) 398,197 Cost of Sales Cost of sales (exclusive of depreciation shown below) — 21,309 138,498 9,360 (3,146 ) 166,021 Gross profit — 34,706 180,415 17,294 (239 ) 232,176 Operating Expenses Advertising and promotion — 5,721 43,161 5,433 — 54,315 General and administrative 2,514 3,855 24,863 2,819 — 34,051 Depreciation and amortization 2,019 293 8,892 203 — 11,407 Total operating expenses 4,533 9,869 76,916 8,455 — 99,773 Operating income (loss) (4,533 ) 24,837 103,499 8,839 (239 ) 132,403 Other (income) expense Interest income (24,210 ) (43,015 ) (2,389 ) (238 ) 69,792 (60 ) Interest expense 17,454 42,211 50,349 2,389 (69,792 ) 42,611 Loss on extinguishment of debt — 451 — — — 451 Equity in (income) loss of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Total other (income) expense (63,503 ) (37,054 ) 43,125 2,151 98,283 43,002 Income (loss) before income taxes 58,970 61,891 60,374 6,688 (98,522 ) 89,401 Provision for income taxes 994 8,917 19,661 1,853 — 31,425 Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Comprehensive (loss) income, net of tax: Currency translation adjustments (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Total other comprehensive (loss) income (11,484 ) (11,484 ) (11,484 ) (11,484 ) 34,452 (11,484 ) Comprehensive income (loss) $ 46,492 $ 41,490 $ 29,229 $ (6,649 ) $ (64,070 ) $ 46,492
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 8,168 $ — $ 292 $ 21,998 $ — $ 30,458 Accounts receivable, net — 11,677 67,356 13,836 — 92,869 Inventories — 12,910 75,088 10,578 (617 ) 97,959 Deferred income tax assets 297 807 8,652 890 — 10,646 Prepaid expenses and other current assets 2,189 546 7,926 680 — 11,341 Assets held for sale — — 36,400 — — 36,400 Total current assets 10,654 25,940 195,714 47,982 (617 ) 279,673 Property and equipment, net 7,963 314 4,889 566 — 13,732 Goodwill — 66,007 263,183 22,472 — 351,662 Intangible assets, net — 191,521 1,901,899 87,708 — 2,181,128 Other long-term assets 2,500 2,283 — — — 4,783 Intercompany receivables 1,478,481 2,573,184 1,461,115 12,506 (5,525,286 ) — Investment in subsidiary 1,665,764 1,538,358 83,983 — (3,288,105 ) — Total Assets $ 3,165,362 $ 4,397,607 $ 3,910,783 $ 171,234 $ (8,814,008 ) $ 2,830,978 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,643 $ 9,422 $ 24,097 $ 2,879 $ — $ 39,041 Accrued interest payable — 8,264 — — — 8,264 Other accrued liabilities 11,731 1,841 47,137 6,297 — 67,006 Total current liabilities 14,374 19,527 71,234 9,176 — 114,311 Long-term debt Principal amount — 1,502,000 — — — 1,502,000 Less unamortized debt costs — (22,337 ) — — — (22,337 ) Long-term debt, net — 1,479,663 — — — 1,479,663 Deferred income tax liabilities — 61,046 398,108 373 — 459,527 Other long-term liabilities — 2,682 155 — 2,837 Intercompany payables 2,376,348 1,246,668 1,821,773 80,497 (5,525,286 ) — Total Liabilities 2,390,722 2,806,904 2,293,797 90,201 (5,525,286 ) 2,056,338 Stockholders' Equity Common stock 532 — — — — 532 Additional paid-in capital 453,336 1,280,947 1,359,921 78,774 (2,719,642 ) 453,336 Treasury stock, at cost (6,558 ) — — — — (6,558 ) Accumulated other comprehensive (loss) income, net of tax (26,646 ) (26,646 ) (26,646 ) (26,646 ) 79,938 (26,646 ) Retained earnings (accumulated deficit) 353,976 336,402 283,711 28,905 (649,018 ) 353,976 Total Stockholders' Equity 774,640 1,590,703 1,616,986 81,033 (3,288,722 ) 774,640 Total Liabilities and Stockholders' Equity $ 3,165,362 $ 4,397,607 $ 3,910,783 $ 171,234 $ (8,814,008 ) $ 2,830,978 Condensed Consolidating Balance Sheet March 31, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Assets Current assets Cash and cash equivalents $ 4,440 $ — $ 2,899 $ 19,891 $ — $ 27,230 Accounts receivable, net — 12,025 74,446 8,776 — 95,247 Inventories — 9,411 72,296 10,088 (532 ) 91,263 Deferred income tax assets 316 681 8,293 818 — 10,108 Prepaid expenses and other current assets 15,311 257 8,379 1,218 — 25,165 Total current assets 20,067 22,374 166,313 40,791 (532 ) 249,013 Property and equipment, net 9,166 210 5,528 636 — 15,540 Goodwill — 66,007 271,409 22,775 — 360,191 Intangible assets, net — 191,789 2,042,640 88,294 — 2,322,723 Other long-term assets — 1,324 — — — 1,324 Intercompany receivables 1,457,011 2,703,192 1,083,488 10,738 (5,254,429 ) — Investment in subsidiary 1,641,477 1,527,718 81,545 — (3,250,740 ) — Total Assets $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,914 $ 7,643 $ 24,437 $ 3,302 $ — $ 38,296 Accrued interest payable — 8,664 — — — 8,664 Other accrued liabilities 12,285 1,714 38,734 6,991 — 59,724 Total current liabilities 15,199 18,021 63,171 10,293 — 106,684 Long-term debt Principal amount — 1,652,500 — — — 1,652,500 Less unamortized debt costs — (27,191 ) — — — (27,191 ) Long-term debt, net — 1,625,309 — — — 1,625,309 Deferred income tax liabilities — 60,317 408,893 412 — 469,622 Other long-term liabilities — — 2,682 158 — 2,840 Intercompany payables 2,368,186 1,241,084 1,570,265 74,894 (5,254,429 ) — Total Liabilities 2,383,385 2,944,731 2,045,011 85,757 (5,254,429 ) 2,204,455 Stockholders' Equity Common stock 530 — — — — 530 Additional paid-in capital 445,182 1,280,947 1,359,921 78,774 (2,719,642 ) 445,182 Treasury stock, at cost (5,163 ) — — — — (5,163 ) Accumulated other comprehensive income (loss), net of tax (23,525 ) (23,525 ) (23,525 ) (23,525 ) 70,575 (23,525 ) Retained earnings (accumulated deficit) 327,312 310,461 269,516 22,228 (602,205 ) 327,312 Total Stockholders' Equity 744,336 1,567,883 1,605,912 77,477 (3,251,272 ) 744,336 Total Liabilities and Stockholders' Equity $ 3,127,721 $ 4,512,614 $ 3,650,923 $ 163,234 $ (8,505,701 ) $ 2,948,791
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2016 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non- Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 26,664 $ 25,941 $ 14,195 $ 6,677 $ (46,813 ) $ 26,664 Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation and amortization 1,752 302 10,550 244 — 12,848 Loss on sales of intangible assets and property and equipment — 55,112 — — 55,112 Deferred income taxes 19 603 (11,144 ) (80 ) — (10,602 ) Amortization of debt origination costs — 5,097 — — — 5,097 Stock-based compensation costs 3,933 — — — — 3,933 Equity in income of subsidiaries (26,290 ) (13,761 ) (6,677 ) — 46,728 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 348 7,090 (7,082 ) — 356 Inventories — (3,499 ) (6,596 ) (653 ) 85 (10,663 ) Prepaid expenses and other current assets 10,622 (289 ) (735 ) 514 — 10,112 Accounts payable (297 ) 1,779 (164 ) (498 ) — 820 Accrued liabilities (554 ) (273 ) 8,284 (852 ) — 6,605 Net cash provided by (used in) operating activities 15,849 16,248 69,915 (1,730 ) — 100,282 Investing Activities Purchases of property and equipment (395 ) (138 ) (785 ) (86 ) — (1,404 ) Proceeds from sales of intangible assets — — 52,353 — — 52,353 Proceeds from the sale of property and equipment — — 75 — — 75 Net cash provided by (used in) investing activities (395 ) (138 ) 51,643 (86 ) — 51,024 Financing Activities Term loan repayments — (130,500 ) — — — (130,500 ) Borrowings under revolving credit agreement — 20,000 — — — 20,000 Repayments under revolving credit agreement — (40,000 ) — — — (40,000 ) Payments of debt origination costs — (9 ) — — — (9 ) Proceeds from exercise of stock options 3,423 — — — — 3,423 Excess tax benefits from share-based awards 800 — — — — 800 Fair value of shares surrendered as payment of tax withholding (1,395 ) — — — — (1,395 ) Intercompany activity, net (14,554 ) 134,399 (124,165 ) 4,320 — — Net cash (used in) provided by financing activities (11,726 ) (16,110 ) (124,165 ) 4,320 — (147,681 ) Effect of exchange rate changes on cash and cash equivalents — — — (397 ) — (397 ) Increase (decrease) in cash and cash equivalents 3,728 — (2,607 ) 2,107 — 3,228 Cash and cash equivalents - beginning of period 4,440 — 2,899 19,891 — 27,230 Cash and cash equivalents - end of period $ 8,168 $ — $ 292 $ 21,998 $ — $ 30,458 Condensed Consolidating Statement of Cash Flows Six Months Ended September 30, 2015 (In thousands) Prestige Brands Holdings, Inc. Prestige Combined Subsidiary Guarantors Combined Non-Guarantor Subsidiaries Eliminations Consolidated Operating Activities Net income (loss) $ 57,976 $ 52,974 $ 40,713 $ 4,835 $ (98,522 ) $ 57,976 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 2,019 293 8,892 203 — 11,407 Gain on sale of property and equipment — — — (36 ) — (36 ) Deferred income taxes 171 254 21,506 54 — 21,985 Amortization of debt origination costs — 4,055 — — — 4,055 Stock-based compensation costs 4,993 — — 41 — 5,034 Loss on extinguishment of debt — 451 — — — 451 Equity in income of subsidiaries (56,747 ) (36,701 ) (4,835 ) — 98,283 — Changes in operating assets and liabilities, net of effects from acquisitions: Accounts receivable — 1,729 (3,550 ) (2,097 ) — (3,918 ) Inventories — (1,017 ) (2,177 ) (883 ) 239 (3,838 ) Prepaid expenses and other current assets 3,166 (402 ) 660 12 — 3,436 Accounts payable 269 624 (3,343 ) (2,069 ) — (4,519 ) Accrued liabilities (2,503 ) (1,094 ) 1,012 1,142 — (1,443 ) Net cash provided by operating activities 9,344 21,166 58,878 1,202 — 90,590 Investing Activities Purchases of property and equipment (1,107 ) (93 ) (103 ) (380 ) — (1,683 ) Proceeds from the sale of property and equipment — — — 344 — 344 Net cash used in investing activities (1,107 ) (93 ) (103 ) (36 ) — (1,339 ) Financing Activities Term loan repayments — (50,000 ) — — — (50,000 ) Borrowings under revolving credit agreement — 15,000 — — — 15,000 Repayments under revolving credit agreement — (55,000 ) — — — (55,000 ) Payments of debt origination costs — (4,211 ) — — — (4,211 ) Proceeds from exercise of stock options 6,398 — — — — 6,398 Proceeds from restricted stock exercises 544 — — — — 544 Excess tax benefits from share-based awards 1,850 — — — — 1,850 Fair value of shares surrendered as payment of tax withholding (2,187 ) — — — — (2,187 ) Intercompany activity, net (15,675 ) 73,138 (58,775 ) 1,312 — — Net cash (used in) provided by financing activities (9,070 ) (21,073 ) (58,775 ) 1,312 — (87,606 ) Effect of exchange rate changes on cash and cash equivalents — — — (811 ) — (811 ) Increase (decrease) in cash and cash equivalents (833 ) — — 1,667 — 834 Cash and cash equivalents - beginning of period 11,387 — — 9,931 — 21,318 Cash and cash equivalents - end of period $ 10,554 $ — $ — $ 11,598 $ — $ 22,152

Business and Basis of Present44

Business and Basis of Presentation (Other Balance Sheet and Income Statement Items) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Ownership percentage, subsidiaries	100.00%		100.00%
Concentration Risk [Line Items]
Warehousing, shipping and handling, and storage costs	$ 10.9	$ 10.4	$ 21.4	$ 19.1
UNITED STATES | Geographic Concentration Risk | Cash
Concentration Risk [Line Items]
Percentage of deposits located in the United States			27.80%

Business and Basis of Present45

Business and Basis of Presentation (Property and Equipment) (Details)	6 Months Ended
	Sep. 30, 2016
Machinery
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	5 years
Computer equipment and software
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years

Business and Basis of Present46

Business and Basis of Presentation (Intangible Assets) (Details)	6 Months Ended
	Sep. 30, 2016
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives	30 years

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Thousands	Feb. 05, 2016	Sep. 30, 2016	Mar. 31, 2016
Business Acquisition [Line Items]
Goodwill		$ 351,662	$ 360,191
DenTek Oral Care, Inc.
Business Acquisition [Line Items]
Purchase price	$ 228,300
Non-amortizable intangible assets	179,800
Amortizable intangible assets	$ 26,900
Purchased amortizable intangible assets, weighted average useful life	18 years 6 months
Purchased amortizable intangible assets, weighted average remaining period		18 years
Goodwill	$ 76,529

Acquisitions (Allocation of Ass

Acquisitions (Allocation of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016	Feb. 05, 2016
Purchase Price
Goodwill	$ 351,662	$ 360,191
DenTek Oral Care, Inc.
Purchase Price
Cash acquired			$ 1,359
Accounts receivable			9,187
Inventories			14,304
Deferred income taxes			3,303
Prepaids and other current assets			6,728
Property, plant and equipment, net			3,555
Goodwill			76,529
Intangible assets, net			206,700
Total assets acquired			321,665
Accounts payable			3,261
Accrued expenses			16,488
Deferred income tax liabilities - long term			73,573
Total liabilities assumed			93,322
Total purchase price			$ 228,343

Divestitures and Assets Held 49

Divestitures and Assets Held For Sale (Divestitures) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Long Lived Assets Held-for-sale [Line Items]
(Gain) loss on sale of assets		$ 496	$ 0	$ (54,957)	$ 0
Disposed of by sale | Pediacare, New Skin and Fiber Choice | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Long Lived Assets Held-for-sale [Line Items]
Disposal group, consideration, excluding costs of inventory	$ 40,000
Proceeds from sale of divestiture	40,100
Cost of inventory	$ 2,600
Holdback term	18 months
Inventory	$ 2,380
Intangible assets, net	91,208
Goodwill	2,920
Assets sold	96,508
Total purchase price to be received	42,380
(Gain) loss on sale of assets	(54,128)
Costs to sell	2,018
Pre-tax loss on sale	56,146
Disposed of by sale | Dermoplast | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Long Lived Assets Held-for-sale [Line Items]
Deposit for agreement to purchase	$ 1,250

Divestitures and Assets Held 50

Divestitures and Assets Held For Sale (Assets Held for Sale) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets Held for Sale	$ 36,400	$ 0
Dermoplast | Held-for-sale, not discontinued operations | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventory	619
Intangible assets, net	31,030
Goodwill	4,751
Assets Held for Sale	$ 36,400

Accounts Receivable (Components

Accounts Receivable (Components of Accounts Receivable) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 104,755	$ 106,853
Less allowances for discounts, returns and uncollectible accounts	(11,886)	(11,606)
Accounts receivable, net	92,869	95,247
Trade accounts receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	103,744	105,592
Other receivables
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 1,011	$ 1,261

Inventories (Components of Inv

Inventories (Components of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Inventory Disclosure [Abstract]
Packaging and raw materials	$ 7,552	$ 7,563
Finished goods	90,407	83,700
Inventories	97,959	91,263
Inventory valuation reserves related to obsolete and slow-moving inventory	$ 4,500	$ 4,800

Property and Equipment (Compone

Property and Equipment (Components of Property and Equipment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Components of Property and Equipment
Property and equipment, gross	$ 30,923		$ 30,923		$ 30,361
Accumulated depreciation	(17,191)		(17,191)		(14,821)
Property and equipment, net	13,732		13,732		15,540
Depreciation expense	1,500	$ 1,200	3,000	$ 2,500
Machinery
Components of Property and Equipment
Property and equipment, gross	8,122		8,122		7,734
Computer equipment
Components of Property and Equipment
Property and equipment, gross	12,928		12,928		12,793
Furniture and fixtures
Components of Property and Equipment
Property and equipment, gross	2,501		2,501		2,445
Leasehold improvements
Components of Property and Equipment
Property and equipment, gross	$ 7,372		$ 7,372		$ 7,389

Goodwill (Schedule of Segment G

Goodwill (Schedule of Segment Goodwill) (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Aug. 31, 2016	Sep. 30, 2016
Goodwill [Roll Forward]
Balance — March 31, 2016		$ 360,191
Reductions		(8,225)
Effects of foreign currency exchange rates		(304)
Balance — September 30, 2016		351,662
North American OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2016		330,615
Reductions		(7,670)
Effects of foreign currency exchange rates		0
Balance — September 30, 2016		322,945
International OTC Healthcare
Goodwill [Roll Forward]
Balance — March 31, 2016		22,776
Reductions		0
Effects of foreign currency exchange rates		(304)
Balance — September 30, 2016		22,472
Household Cleaning
Goodwill [Roll Forward]
Balance — March 31, 2016		6,800
Reductions	$ (600)	(555)
Effects of foreign currency exchange rates		0
Balance — September 30, 2016		$ 6,245

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($)	Jul. 07, 2016	Aug. 31, 2016	Sep. 30, 2016	Mar. 31, 2016
Goodwill [Line Items]
Reduced Goodwill amount			$ 8,225,000
Goodwill impairment				$ 0
Household Cleaning
Goodwill [Line Items]
Reduced Goodwill amount		$ 600,000	555,000
North American OTC Healthcare
Goodwill [Line Items]
Reduced Goodwill amount			7,670,000
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Disposed of by sale | North American OTC Healthcare | Pediacare, New Skin and Fiber Choice
Goodwill [Line Items]
Disposal group, consideration, excluding costs of inventory	$ 40,000,000
Proceeds from sale of divestiture	40,100,000
Disposal group, goodwill	$ 2,920,000
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Held-for-sale, not discontinued operations | North American OTC Healthcare | Dermoplast
Goodwill [Line Items]
Goodwill transferred to assets held for sale			$ 4,751,000

Intangible Assets (Schedule of

Intangible Assets (Schedule of Reconciliation of Activity Affecting Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Mar. 31, 2016
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		$ 2,020,046
Indefinite Lived Trademarks, ending balance	$ 1,942,418	1,942,418
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance		115,203
Accumulated amortization, reclassified to assets held for sale		(6,102)
Accumulated amortization, additions	4,600	9,865
Accumulated amortization, effects of foreign exchange rates		(2)
Finite Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	118,964	118,964
Intangible Assets, Gross [Abstract]
Totals, gross, beginning balance		2,437,926
Totals, reclassified to assets held for sale		137,351
Totals, effects of foreign currency exchange rate		(483)
Totals, gross, ending balance	2,300,092	2,300,092
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	238,710	238,710	$ 302,677
Intangible Assets, Net [Abstract]
Intangible assets, net	2,181,128	2,181,128	2,322,723
North American OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	1,971,453	1,971,453	2,101,635
International OTC Healthcare
Intangible Assets, Net [Abstract]
Intangible assets, net	86,607	86,607	88,138
Household Cleaning
Intangible Assets, Net [Abstract]
Intangible assets, net	123,068	123,068	132,950
Finite Lived Trademarks and Customer Relationships
Finite-Lived Intangible Assets, Gross [Abstract]
Finite Lived Trademarks and Customer Relationships, beginning balance		417,880
Finite-Lived Trademarks and Customer Relationships, reclassified to assets held for sale		(60,103)
Finite Lived Trademarks and Customer Relationships, effects of foreign currency exchange rate		(103)
Finite Lived Trademarks and Customer Relationships, ending balance	357,674	357,674
Finite-lived Intangible Assets, Accumulated Amortization [Abstract]
Finite Lived Trademarks and Customer Relationships, accumulated amortization, beginning balance		115,203
Accumulated amortization, reclassified to assets held for sale		(6,102)
Accumulated amortization, additions		9,865
Accumulated amortization, effects of foreign exchange rates		(2)
Finite Lived Trademarks and Customer Relationships, accumulated amortization, ending balance	118,964	118,964
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	238,710	238,710
Finite Lived Trademarks and Customer Relationships | North American OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	215,817	215,817	277,762
Finite Lived Trademarks and Customer Relationships | International OTC Healthcare
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	1,087	1,087	2,237
Finite Lived Trademarks and Customer Relationships | Household Cleaning
Finite-Lived Intangible Assets, Net [Abstract]
Intangible assets, net	21,806	21,806	$ 22,678
Indefinite Lived Trademarks
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		2,020,046
Indefinite-Lived Trademarks, reclassified to assets held for sale		(77,248)
Indefinite Lived Trademarks, effects of foreign currency exchange rate		(380)
Indefinite Lived Trademarks, ending balance	1,942,418	1,942,418
Indefinite Lived Trademarks | North American OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		1,823,873
Indefinite Lived Trademarks, ending balance	1,755,636	1,755,636
Indefinite Lived Trademarks | International OTC Healthcare
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		85,901
Indefinite Lived Trademarks, ending balance	85,520	85,520
Indefinite Lived Trademarks | Household Cleaning
Indefinite-Lived Intangible Assets [Abstract]
Indefinite Lived Trademarks, beginning balance		110,272
Indefinite Lived Trademarks, ending balance	$ 101,262	$ 101,262

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Thousands	Jul. 07, 2016	Aug. 31, 2016	Dec. 31, 2014	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Proceeds from sales of intangible assets					$ 52,353	$ 0
Purchased amortizable intangible assets, weighted average remaining period					13 years 1 month 24 days
Amortization expense				$ 4,600	$ 9,865
Minimum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives					10 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful lives					30 years
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Pediacare, New Skin and Fiber Choice | Disposed of by sale
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period decrease	$ 37,200
Disposal group, consideration, excluding costs of inventory	40,000
Proceeds from sale of divestiture	40,100
Finite-lived intangible assets, reclassified to assets held for sale	54,000
Pre-tax loss on sale	56,146
Indefinite- lived intangible assets reclassified as held for sale	$ 91,208
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Pediacare, New Skin and Fiber Choice | Held-for-sale, not discontinued operations
Finite-Lived Intangible Assets [Line Items]
Pre-tax loss on sale				700	$ 56,146
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Dermoplast | Held-for-sale, not discontinued operations
Finite-Lived Intangible Assets [Line Items]
Indefinite- lived intangible assets reclassified as held for sale				$ 31,000	31,000
Comet Brand
Finite-Lived Intangible Assets [Line Items]
Proceeds from sales of intangible assets		$ 11,000	$ 10,000		$ 1,000
Gain on sale of intangible assets		1,200
Trademarks
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets, period decrease		$ 9,000

Intangible Assets (Expected Amo

Intangible Assets (Expected Amortization Expense) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2017 (Remaining six months ending March 31, 2017)	$ 9,113
2,018	18,062
2,019	18,062
2,020	18,062
2,021	17,640
Thereafter	157,771
Intangible assets, net	$ 238,710	$ 302,677

Other Accrued Liabilities (Summ

Other Accrued Liabilities (Summary of Accrued Liabilities and Accounts Payable) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Payables and Accruals [Abstract]
Accrued marketing costs	$ 29,938	$ 26,373
Accrued compensation costs	5,572	9,574
Accrued broker commissions	965	1,497
Income taxes payable	10,284	3,675
Accrued professional fees	3,050	1,787
Deferred rent	690	836
Accrued production costs	3,023	3,324
Accrued lease termination costs	384	448
Income tax related payable	6,354	6,354
Other accrued liabilities	6,746	5,856
Total other accrued liabilities	$ 67,006	$ 59,724

Long-Term Debt (2012 Term Loan

Long-Term Debt (2012 Term Loan and 2012 ABL Revolver) (Details) - USD ($)

Feb. 04, 2016

Jun. 09, 2015

Sep. 03, 2014

Feb. 21, 2013

Jan. 31, 2012

Sep. 30, 2016

Sep. 30, 2015

Mar. 31, 2013

Sep. 30, 2016

Sep. 30, 2015

Mar. 31, 2015

Mar. 31, 2016

May 08, 2015

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 0

$ 0

$ 0

$ 451,000

Term Loan and ABL Revolver 2012

Debt Instrument [Line Items]

Debt issuance costs capitalized

$ 20,600,000

2012 ABL Revolver | Revolving Credit Facility

Debt Instrument [Line Items]

Debt instrument, maturity term

5 years

Line of credit facility, maximum borrowing capacity

$ 50,000,000

135,000,000

135,000,000

Line of credit facility, increase in borrowing capacity

$ 85,000,000

$ 85,000,000

Debt instrument, interest rate, increase/(decrease) (percent)

(0.25%)

Line of credit facility, commitment fee percentage

0.50%

Line of credit facility, conditional commitment fee percentage

0.375%

Line of credit facility, increase in accordion feature

$ 35,000,000

Long-term debt, weighted average interest rate

2.40%

2.40%

2012 ABL Revolver | Revolving Credit Facility | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

1.00%

2012 ABL Revolver | Revolving Credit Facility | LIBOR | Minimum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

2.00%

2012 ABL Revolver | Revolving Credit Facility | LIBOR | Maximum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

2.25%

2012 ABL Revolver | Revolving Credit Facility | Base Rate | Minimum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

1.00%

2012 ABL Revolver | Revolving Credit Facility | Base Rate | Maximum

Debt Instrument [Line Items]

Debt instrument, conditional variable rate (percent)

1.25%

2012 ABL Revolver | Revolving Credit Facility | Federal Funds Rate

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

0.50%

2012 ABL Revolver Amendment 3 | Revolving Credit Facility

Debt Instrument [Line Items]

Line of credit facility, increase in borrowing capacity

$ 40,000,000

2012 ABL Revolver Amendment 5 | Revolving Credit Facility

Debt Instrument [Line Items]

Temporary suspension of financial reporting covenant, period

60 days

Senior Notes | 2012 Senior Notes

Debt Instrument [Line Items]

Debt instrument, face amount

$ 660,000,000

Debt instrument, stated interest rate (percent)

8.125%

Term Loans | 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, maturity term

7 years

Debt instrument, discount, percentage

1.50%

Proceeds from issuance of long-term debt

$ 650,100,000

Term Loans | Amendment 1, 2012 Term Loan

Debt Instrument [Line Items]

Loss on extinguishment of debt

$ 1,400,000

Term Loans | Amendment 1, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

2.75%

Debt instrument, reference rate floor (percent)

1.00%

Term Loans | Amendment 1, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

2.00%

Term Loans | Amendment 2, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

1.00%

Term Loans | Amendment 2, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

3.125%

Term Loans | Amendment 2, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

2.00%

Term Loans | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, average interest rate during period (percent)

5.00%

Term Loans | Amendment 3, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

1.00%

Term Loans | Amendment 3, 2012 Term Loan | LIBOR | Minimum

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

0.75%

Term Loans | Amendment 3, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

1.75%

Term Loans | Amendment 3, 2012 Term Loan | Federal Funds Rate

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate, fixed component (percent)

0.50%

Term B-2 | Amendment 2, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

$ 720,000,000

Term B-2 | Amendment 2, 2012 Term Loan | LIBOR

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate (percent)

3.50%

Debt instrument, reference rate floor (percent)

1.00%

Term B-2 | Amendment 2, 2012 Term Loan | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

2.00%

Debt instrument, step down interest rate (percent)

3.25%

Term B-2 | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

$ 645,000,000

Loans Payable, Term B-3 | 2012 Senior Notes | LIBOR

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

0.75%

0.75%

0.75%

Loans Payable, Term B-3 | 2012 Senior Notes | Base Rate

Debt Instrument [Line Items]

Debt instrument, reference rate floor (percent)

1.75%

1.75%

1.75%

Loans Payable, Term B-3 | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

852,500,000

Loans Payable, Term B-1 | Amendment 3, 2012 Term Loan

Debt Instrument [Line Items]

Debt instrument, face amount

$ 207,500,000

Long-Term Debt (Senior Notes) (

Long-Term Debt (Senior Notes) (Details) - Senior Notes - USD ($)	Sep. 30, 2016	Mar. 31, 2016	Feb. 19, 2016	Dec. 17, 2013
2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount			$ 350,000,000
Debt instrument, stated interest rate (percent)	6.375%	6.375%	6.375%
Debt issuance costs capitalized			$ 5,500,000
2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, face amount				$ 400,000,000
Debt instrument, stated interest rate (percent)	5.375%	5.375%		5.375%
Debt issuance costs capitalized				$ 7,200,000

Long-Term Debt (Redemptions and

Long-Term Debt (Redemptions and Restrictions) (Details) - USD ($) $ in Millions	Feb. 19, 2016	Sep. 30, 2016	Sep. 30, 2016	Mar. 31, 2016
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		$ 22.3	$ 22.3	$ 27.2
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Term loan repayments		65
Line of credit facility, remaining borrowing capacity		68.2	68.2
2012 ABL Revolver | Revolving Credit Facility | Other long-term assets
Debt Instrument [Line Items]
Unamortized debt costs related to 2012 ABL Revolver		1.1	$ 1.1	1.3
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage			101.00%
Unamortized discount (premium) and debt issuance costs, net		5	$ 5	5.4
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		5.1	5.1	5.4
Term Loans | 2012 Term Loan
Debt Instrument [Line Items]
Unamortized discount (premium) and debt issuance costs, net		$ 12.2	$ 12.2	$ 16.4
Debt Instrument, Redemption, Period One | Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage			100.00%
Redemption price, percentage of principal amount, using proceeds of equity offerings			105.375%
Debt Instrument, Redemption, Period Two | Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	100.00%
Maximum | Debt Instrument, Redemption, Period One | Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed			35.00%
Maximum | Debt Instrument, Redemption, Period Two | Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Redemption price, percentage of principal amount redeemed	40.00%
Indirect Guarantee of Indebtedness | Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, redemption price, percentage	101.00%

Long-Term Debt (Schedule of Lon

Long-Term Debt (Schedule of Long-term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016	Feb. 19, 2016	Dec. 17, 2013	Feb. 21, 2013
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,502,000	$ 1,652,500
Current portion of long-term debt	0	0
Principal amount	1,502,000	1,652,500
Less: unamortized debt costs	(22,337)	(27,191)
Long-term debt, net	1,479,663	1,625,309
2012 ABL Revolver | Revolving Credit Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 65,000	$ 85,000
Senior Notes | 2016 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	6.375%	6.375%	6.375%
Long-term debt, gross	$ 350,000	$ 350,000
Senior Notes | 2013 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)	5.375%	5.375%		5.375%
Long-term debt, gross	$ 400,000	$ 400,000
Senior Notes | 2012 Senior Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate (percent)					8.125%
Loans Payable, Term B-3 | 2012 Senior Notes
Debt Instrument [Line Items]
Long-term debt, gross	$ 687,000	$ 817,500
Loans Payable, Term B-3 | 2012 Senior Notes | Base Rate
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	1.75%	1.75%
Loans Payable, Term B-3 | 2012 Senior Notes | LIBOR
Debt Instrument [Line Items]
Debt instrument, reference rate floor (percent)	0.75%	0.75%

Long-Term Debt (Maturities of L

Long-Term Debt (Maturities of Long-term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Debt Disclosure [Abstract]
2017 (remaining six months ending March 31, 2017)	$ 0
2,018	0
2,019	0
2,020	0
2,021	65,000
Thereafter	1,437,000
Long-term debt, gross	$ 1,502,000	$ 1,652,500

Fair Value Measurements (Summar

Fair Value Measurements (Summary of Carrying Amounts and Estimated Fair Values) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Senior Notes | 2016 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	$ 350,000	$ 350,000
Senior Notes | 2013 Senior Notes | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	400,000	400,000
Term B-3 Loans | 2012 Term Loan | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	687,000	817,500
Revolving Credit Facility | 2012 ABL Revolver | Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	65,000	85,000
Fair Value, Measurements, Recurring | Senior Notes | 2016 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	371,000	363,125
Fair Value, Measurements, Recurring | Senior Notes | 2013 Senior Notes | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	414,000	408,000
Fair Value, Measurements, Recurring | Term B-3 Loans | 2012 Term Loan | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, senior notes and term loans	693,011	818,522
Fair Value, Measurements, Recurring | Revolving Credit Facility | 2012 ABL Revolver | Fair Value | Fair Value, Inputs, Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
2012 ABL Revolver	$ 65,000	$ 85,000

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2016vote$ / sharesshares	Sep. 30, 2015shares	Sep. 30, 2016USD ($)vote$ / sharesshares	Sep. 30, 2015$ / sharesshares	Mar. 31, 2016$ / sharesshares
Class of Stock [Line Items]
Common stock, shares authorized (in shares) | shares	250,000,000		250,000,000		250,000,000
Common stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares authorized (in shares) | shares	5,000,000		5,000,000		5,000,000
Preferred stock, par value (in USD per share) | $ / shares	$ 0.01		$ 0.01		$ 0.01
Voting rights, number of votes per common share owned | vote	1		1
Dividends declared on common stock | $			$ 0
Restricted Shares
Class of Stock [Line Items]
Restricted stock repurchased during period (shares) | shares	0	0	24,988	39,429
Restricted stock acquired, average cost per share (in USD per share) | $ / shares			$ 55.82	$ 41.66

Accumulated Other Comprehensi67

Accumulated Other Comprehensive Loss (Components of AOCI) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive loss, net of tax	$ (26,646)	$ (23,525)
Accumulated foreign currency adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cumulative translation adjustment	$ (26,646)	$ (23,525)

(Computation of Basis and Dilut

(Computation of Basis and Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator
Net income	$ 32,195	$ 31,803	$ 26,664	$ 57,976
Denominator
Denominator for basic earnings per share — weighted average shares outstanding (in shares)	52,993	52,803	52,941	52,676
Dilutive effect of unvested restricted stock units and options issued to employees and directors (in shares)	352	348	388	379
Denominator for diluted earnings per share (in shares)	53,345	53,151	53,329	53,055
Earnings per Common Share:
Basic net earnings per share (in USD per share)	$ 0.61	$ 0.60	$ 0.50	$ 1.10
Diluted net earnings per share (in USD per share)	$ 0.60	$ 0.60	$ 0.50	$ 1.09

Earnings Per Share (Antidilutiv

Earnings Per Share (Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0.2	0.2	0.2	0.2

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) $ / shares in Units, $ in Millions	Sep. 12, 2016$ / sharesshares	Aug. 02, 2016shares	May 26, 2016shares	May 09, 2016$ / sharesshares	May 31, 2014shares	Jun. 30, 2014shares	Sep. 30, 2016USD ($)directorshares	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)director$ / sharesshares	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation, Aggregate Disclosures:
Number of shares authorized for grant under 2005 Long-Term Equity Incentive Plan (in shares)							5,000,000		5,000,000
Number of additional shares authorized (in shares)						1,800,000
Maximum number of shares per participant, 12 month period (in shares)					1,000,000	2,500,000
Extension of plan term						10 years
Share-based compensation costs charged against income | $							$ 2	$ 2	$ 3.9	$ 5
Tax benefit recognized from share-based compensation expense | $							0.5	$ 0.7	1.2	1.8
Unrecognized compensation costs related to nonvested awards | $							$ 12.4		$ 12.4
Unrecognized compensation costs related to nonvested awards, weighted average period for recognition									1 year
Total fair value of vested shares | $									$ 6	6.5
Cash received from exercise of stock options | $									3.4	6.4
Tax benefit realized from exercise of stock options | $									$ 1.7	$ 3.5
Shares available for issuance under the Plan (in shares)							2,400,000		2,400,000
Stock options granted (in shares)									250,600	200,100
Restricted Shares
Board of directors, number of directors | director							6		6
Options, Additional Disclosures:
Options granted, weighted-average grant-date fair value (in USD per share) | $ / shares									$ 21.87	$ 17.10
Options exercised, aggregate intrinsic value | $									$ 2.4
Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Shares issued in period (in shares)									92,718	153,603
Granted in period to each independent director (in shares)		1,896		49,064					65,800	259,500
Award vesting period				3 years
Restricted Shares
Period following director's term in which RSUs may be settled		6 months
Granted, weighted-average grant-date fair value (in USD per share) | $ / shares									$ 55.65	$ 42.20
Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)				224,843
Award vesting period				3 years
Expected term in years				10 years
Stock options granted, exercise price (in USD per share) | $ / shares				$ 57.18
Stock Options | Minimum
Share-based Compensation, Aggregate Disclosures:
Award vesting period									3 years
Stock Options | Maximum
Share-based Compensation, Aggregate Disclosures:
Award vesting period									5 years
Options, Additional Disclosures:
Award exercisability period, from date of grant									10 years
Restricted Shares | Minimum
Share-based Compensation, Aggregate Disclosures:
Award vesting period									3 years
Restricted Shares | Maximum
Share-based Compensation, Aggregate Disclosures:
Award vesting period									5 years
Chief Financial Officer | Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period to each independent director (in shares)	5,012
Award vesting period				3 years
Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Stock options granted (in shares)	25,746
Expected term in years	10 years
Stock options granted, exercise price (in USD per share) | $ / shares	$ 47.39
Employee | Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Award vesting period									3 years
Director | Restricted Stock Units (RSUs)
Share-based Compensation, Aggregate Disclosures:
Granted in period to each independent director (in shares)			346
Restricted Shares
Number of common shares into which each RSU may be converted (in shares)		1
Director | Restricted Shares
Share-based Compensation, Aggregate Disclosures:
Award vesting period									1 year
First year anniversary | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage				33.30%
First year anniversary | Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage	33.30%
Second year anniversary | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage				33.30%
Second year anniversary | Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage	33.30%
Third year anniversary | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage				33.30%
Third year anniversary | Chief Financial Officer | Stock Options
Share-based Compensation, Aggregate Disclosures:
Annual award vesting percentage	33.30%

Share-Based Compensation (Restr

Share-Based Compensation (Restricted Stock Units Activity) (Details) - Restricted Stock Units (RSUs) - $ / shares	Aug. 02, 2016	May 09, 2016	Sep. 30, 2016	Sep. 30, 2015
Shares
Outstanding, beginning of period (in shares)			467,800	362,300
Granted (in shares)	1,896	49,064	65,800	259,500
Vested and issued (in shares)			(92,700)	(153,600)
Forfeited (in shares)			(91,000)	(1,400)
Outstanding, end of period (in shares)			349,900	466,800
Vested, end of period (in shares)			63,400	69,800
Weighted- Average Grant-Date Fair Value
Outstanding, beginning of period, weighted-average grant-date fair value (in USD per share)			$ 35.22	$ 22.74
Granted, weighted-average grant-date fair value (in USD per share)			55.65	42.20
Vested and issued, weighted-average grant-date fair value (in USD per share)			28.47	18.16
Forfeited, weighted-average grant-date fair value (in USD per share)			41.69	33.50
Outstanding, end of period, weighted-average grant-date fair value (in USD per share)			39.16	35.03
Vested, end of period, weighted-average grant-date fair value (in USD per share)			$ 20.12	$ 14.76

Share-Based Compensation (Stock

Share-Based Compensation (Stock Option Valuation Assumptions) (Details) - Stock Options - USD ($)	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	37.80%	40.20%
Expected dividends	$ 0	$ 0
Expected term in years	6 years	6 years
Risk-free rate	1.70%	1.70%

Share-Based Compensation (Sto73

Share-Based Compensation (Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Shares
Outstanding, beginning of period (in shares)	727,700	871,200
Granted (in shares)	250,600	200,100
Exercised (in shares)	(107,100)	(336,900)
Forfeited or expired (in shares)	(90,700)	(2,100)
Outstanding, end of period (in shares)	780,500	732,300
Exercisable, end of period (in shares)	383,700	319,500
Weighted- Average Exercise Price
Outstanding, beginning of period, weighted-average exercise price (in USD per share)	$ 30.70	$ 23.40
Granted, weighted-average exercise price (in USD per share)	56.17	41.80
Exercised, weighted-average exercise price (in USD per share)	31.97	18.99
Forfeited or expired, weighted-average exercise price (in USD per share)	42.56	38.16
Outstanding, end of period, weighted-average exercise price (in USD per share)	37.33	30.42
Exercisable, end of period, weighted-average exercise price (in USD per share)	$ 25.61	$ 21.91
Options, Additional Disclosures:
Outstanding, end of period, weighted-average remaining contractual term	7 years 6 months	8 years 1 month 1 day
Exercisable, end of period, weighted-average remaining contractual term	6 years 6 months	7 years
Outstanding, end of period, aggregate intrinsic value	$ 10,326	$ 10,816
Exercisable, end of period, aggregate intrinsic value	$ 8,693	$ 7,430

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Effective income tax rate (percent)	35.90%	35.40%	35.50%	35.20%
Realized reduction in deferred tax liabilities from sale of assets			$ 27.5
Ownership percentage, subsidiaries	100.00%		100.00%
Net operating loss carryforwards	$ 14		$ 14
Deferred tax assets, operating loss carryforwards	5		5
Operating loss carryforwards, limitation on use, annual amount	33.6		33.6
Uncertain tax liability	$ 4.1		$ 4.1		$ 4.1

Commitments and Contingencies75

Commitments and Contingencies (Future Minimum Rental Payments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Operating Leased Assets [Line Items]
2017 (Remaining six months ending March 31, 2017)	$ 1,124		$ 1,124
2,018	2,181		2,181
2,019	2,175		2,175
2,020	1,937		1,937
2,021	903		903
Thereafter	59		59
Total future minimum payments due	8,379		8,379		$ 8,434
Less: Sublease rentals	(1,036)		(1,036)		(1,165)
Minimum lease payments, less minimum sublease rentals	7,343		7,343		$ 7,269
Rent expense	500	$ 400	1,100	$ 800
Facilities
Operating Leased Assets [Line Items]
2017 (Remaining six months ending March 31, 2017)	1,048		1,048
2,018	2,029		2,029
2,019	2,023		2,023
2,020	1,848		1,848
2,021	903		903
Thereafter	59		59
Total future minimum payments due	7,910		7,910
Equipment
Operating Leased Assets [Line Items]
2017 (Remaining six months ending March 31, 2017)	76		76
2,018	152		152
2,019	152		152
2,020	89		89
2,021	0		0
Thereafter	0		0
Total future minimum payments due	$ 469		$ 469

Commitments and Contingencies76

Commitments and Contingencies (Long-term Supply Agreement) (Details) - Third-party Manufacturing - USD ($) $ in Thousands	Nov. 01, 2009	Sep. 30, 2016
Long-term Purchase Commitment [Line Items]
Supply agreement, term	10 years
2017 (Remaining six months ending March 31, 2017)		$ 518
2,018		1,013
2,019		982
2,020		559
2,021		0
Total purchase commitment		$ 3,072

Concentrations of Risk (Narrati

Concentrations of Risk (Narrative) (Details)	3 Months Ended		6 Months Ended
	Sep. 30, 2016manufacturer	Sep. 30, 2015manufacturer	Sep. 30, 2016manufacturercustomer	Sep. 30, 2015manufacturer
Concentration Risk [Line Items]
Number of third-party manufacturers	116	102	116	102
Sales | Product Concentration Risk | Top 5 Customers
Concentration Risk [Line Items]
Concentration risk, percentage	41.60%	41.70%	42.00%	42.80%
Sales | Customer Concentration Risk | Walmart and Walgreen
Concentration Risk [Line Items]
Number of customers exceeding concentration risk benchmark | customer			2
Sales | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage	21.10%	19.60%	20.90%	19.70%
Sales | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage	10.70%	10.00%	10.50%	9.70%
Sales | Supplier Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage			78.80%	81.30%
Number of third-party manufacturers with long-term contracts			49	48
Accounts Receivable | Customer Concentration Risk | Walmart
Concentration Risk [Line Items]
Concentration risk, percentage			23.50%
Accounts Receivable | Customer Concentration Risk | Walgreens
Concentration Risk [Line Items]
Concentration risk, percentage			10.60%

Business Segments (Information

Business Segments (Information on Operating and Reportable Segments) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information, Profit (Loss):
Gross segment revenues	$ 215,017	$ 205,262	$ 423,787	$ 396,549
Other revenues	35	803	840	1,648
Total revenues	215,052	206,065	424,627	398,197
Cost of sales	91,087	86,125	179,071	166,021
Gross profit	123,965	119,940	245,556	232,176
Advertising and promotion	28,592	27,893	56,227	54,315
Contribution margin	95,373	92,047	189,329	177,861
Other operating expenses	24,315	22,149	106,057	45,458
Operating income	71,058	69,898	83,272	132,403
Other expense	20,830	20,667	41,957	43,002
Income before income taxes	50,228	49,231	41,315	89,401
Provision for income taxes	18,033	17,428	14,651	31,425
Net income	32,195	31,803	26,664	57,976
North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues	172,447	165,414	344,527	321,778
Other revenues	0	0	0	15
Total revenues	172,447	165,414	344,527	321,793
Cost of sales	65,402	61,497	129,636	119,624
Gross profit	107,045	103,917	214,891	202,169
Advertising and promotion	24,811	24,440	49,851	47,635
Contribution margin	82,234	79,477	165,040	154,534
International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues	18,802	15,954	34,602	29,410
Other revenues	2	6	6	31
Total revenues	18,804	15,960	34,608	29,441
Cost of sales	7,096	6,094	14,044	11,383
Gross profit	11,708	9,866	20,564	18,058
Advertising and promotion	3,244	2,777	5,368	5,500
Contribution margin	8,464	7,089	15,196	12,558
Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues	23,768	23,894	44,658	45,361
Other revenues	33	797	834	1,602
Total revenues	23,801	24,691	45,492	46,963
Cost of sales	18,589	18,534	35,391	35,014
Gross profit	5,212	6,157	10,101	11,949
Advertising and promotion	537	676	1,008	1,180
Contribution margin	4,675	5,481	9,093	10,769
Operating Segments
Segment Reporting Information, Profit (Loss):
Gross segment revenues	215,160	206,734	425,151	398,749
Operating Segments | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues	172,590	166,886	345,891	323,978
Total revenues	172,447	165,414	344,527	321,793
Operating Segments | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues	18,802	15,954	34,602	29,410
Total revenues	18,804	15,960	34,608	29,441
Operating Segments | Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues	23,768	23,894	44,658	45,361
Total revenues	23,801	24,691	45,492	46,963
Intersegment Eliminations
Segment Reporting Information, Profit (Loss):
Gross segment revenues	(143)	(1,472)	(1,364)	(2,200)
Intersegment Eliminations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues	(143)	(1,472)	(1,364)	(2,200)
Intersegment Eliminations | International OTC Healthcare
Segment Reporting Information, Profit (Loss):
Gross segment revenues	0	0	0	0
Intersegment Eliminations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Gross segment revenues	0	$ 0	0	$ 0
Pediacare, New Skin and Fiber Choice | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Held-for-sale, not discontinued operations | North American OTC Healthcare
Segment Reporting Information, Profit (Loss):
Pre-tax loss on sale	700		56,146
Comet Brand | Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Held-for-sale, not discontinued operations | Household Cleaning
Segment Reporting Information, Profit (Loss):
Pre-tax loss on sale	$ (1,200)		$ 1,200

Business Segments (Revenue by P

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	$ 215,052	$ 206,065	$ 424,627	$ 398,197
Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	30,537	30,382	59,190	57,760
Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	26,266	29,202	48,625	53,467
Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	33,903	34,411	67,726	68,019
Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	22,368	24,403	45,730	48,531
Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	25,923	27,741	54,726	56,003
Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	23,519	23,808	46,888	44,437
Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	27,188	9,922	53,216	20,093
Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	1,547	1,505	3,034	2,924
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	23,801	24,691	45,492	46,963
North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	172,447	165,414	344,527	321,793
International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	18,804	15,960	34,608	29,441
Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	23,801	24,691	45,492	46,963
Operating Segments | North American OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	172,447	165,414	344,527	321,793
Operating Segments | North American OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	29,993	29,694	58,119	56,542
Operating Segments | North American OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	21,106	24,456	39,073	44,215
Operating Segments | North American OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	33,268	33,607	66,155	66,515
Operating Segments | North American OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	16,280	19,061	35,386	39,381
Operating Segments | North American OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	22,934	24,163	48,941	49,223
Operating Segments | North American OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	22,952	23,197	45,650	43,292
Operating Segments | North American OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	24,368	9,733	48,179	19,710
Operating Segments | North American OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	1,546	1,503	3,024	2,915
Operating Segments | International OTC Healthcare
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	18,804	15,960	34,608	29,441
Operating Segments | International OTC Healthcare | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	544	688	1,071	1,218
Operating Segments | International OTC Healthcare | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	5,160	4,746	9,552	9,252
Operating Segments | International OTC Healthcare | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	635	804	1,571	1,504
Operating Segments | International OTC Healthcare | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	6,088	5,342	10,344	9,150
Operating Segments | International OTC Healthcare | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	2,989	3,578	5,785	6,780
Operating Segments | International OTC Healthcare | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	567	611	1,238	1,145
Operating Segments | International OTC Healthcare | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	2,820	189	5,037	383
Operating Segments | International OTC Healthcare | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	1	2	10	9
Operating Segments | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	23,801	24,691	45,492	46,963
Operating Segments | Household Cleaning | Analgesics
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Cough & Cold
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Women's Health
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Gastrointestinal
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Eye & Ear Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Dermatologicals
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Oral Care
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Other OTC
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	0	0	0	0
Operating Segments | Household Cleaning | Household Cleaning
Geographic Areas, Revenues from External Customers [Abstract]
Total segment revenues	$ 23,801	$ 24,691	$ 45,492	$ 46,963

Business Segments (Assets by Se

Business Segments (Assets by Segment) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	$ 351,662		$ 351,662		$ 360,191
Indefinite-lived	1,942,418		1,942,418		2,020,046
Finite-lived	238,710		238,710		302,677
Intangible assets, net	2,181,128		2,181,128		2,322,723
Intangible assets, net (including goodwill)	2,532,790		2,532,790		2,682,914
Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	238,710		238,710
Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	1,942,418		1,942,418		2,020,046
North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	322,945		322,945		330,615
Intangible assets, net	1,971,453		1,971,453		2,101,635
Intangible assets, net (including goodwill)	2,294,398		2,294,398		2,432,250
North American OTC Healthcare | Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	215,817		215,817		277,762
North American OTC Healthcare | Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	1,755,636		1,755,636		1,823,873
International OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	22,472		22,472		22,776
Intangible assets, net	86,607		86,607		88,138
Intangible assets, net (including goodwill)	109,079		109,079		110,914
International OTC Healthcare | Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	1,087		1,087		2,237
International OTC Healthcare | Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	85,520		85,520		85,901
Household Cleaning
Segment Reporting, Asset Reconciling Item [Line Items]
Goodwill	6,245		6,245		6,800
Intangible assets, net	123,068		123,068		132,950
Intangible assets, net (including goodwill)	129,313		129,313		139,750
Household Cleaning | Finite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Finite-lived	21,806		21,806		22,678
Household Cleaning | Indefinite Lived Intangibles
Segment Reporting, Asset Reconciling Item [Line Items]
Indefinite-lived	$ 101,262		$ 101,262		$ 110,272
Sales | UNITED STATES | Geographic Concentration Risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage	85.80%	85.80%	86.70%	86.50%
Sales | CANADA | Geographic Concentration Risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage	5.40%	5.50%	5.10%	5.30%
Sales | AUSTRALIA | Geographic Concentration Risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage	5.90%	6.80%	5.50%	6.30%
Goodwill and Intangible Assets | UNITED STATES | Geographic Concentration Risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage			95.70%		95.70%
Goodwill and Intangible Assets | Australia and United Kingdom | Geographic Concentration Risk
Segment Reporting, Asset Reconciling Item [Line Items]
Concentration risk, percentage			4.30%		4.30%
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | Held-for-sale, not discontinued operations | Pediacare, New Skin and Fiber Choice | North American OTC Healthcare
Segment Reporting, Asset Reconciling Item [Line Items]
Pre-tax loss on sale	$ 700		$ 56,146

Condensed Consolidating Finan81

Condensed Consolidating Financial Statements (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision for income taxes	$ 18,033		$ 17,428	$ 14,651	$ 31,425
Equity in (income) loss of subsidiaries	0		0	0	0
Eliminations
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Provision for income taxes	0		0	0	0
Equity in (income) loss of subsidiaries	$ (62,649)		$ (54,572)	$ (46,728)	$ (98,283)
Restatement adjustment | Overstatement of equity in earnings of subsidiaries
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Equity in (income) loss of subsidiaries		$ (44,600)
Restatement adjustment | Eliminations | Overstatement of equity in earnings of subsidiaries
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Equity in (income) loss of subsidiaries		$ (44,600)

Condensed Consolidating Finan82

Condensed Consolidating Financial Statements (Condensed Consolidating Statements of Income and Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues
Net sales	$ 215,017	$ 205,262	$ 423,787	$ 396,549
Other revenues	35	803	840	1,648
Cost of Sales	215,052	206,065	424,627	398,197
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	91,087	86,125	179,071	166,021
Gross profit	123,965	119,940	245,556	232,176
Operating Expenses
Advertising and promotion	28,592	27,893	56,227	54,315
General and administrative	18,795	16,462	38,252	34,051
Depreciation and amortization	6,016	5,687	12,848	11,407
(Gain) loss on sale of assets	(496)	0	54,957	0
Total operating expenses	52,907	50,042	162,284	99,773
Operating income (loss)	71,058	69,898	83,272	132,403
Other (income) expense
Interest income	(46)	(33)	(103)	(60)
Interest expense	20,876	20,700	42,060	42,611
Loss on extinguishment of debt	0	0	0	451
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	20,830	20,667	41,957	43,002
Provision for income taxes	18,033	17,428	14,651	31,425
Income before income taxes	50,228	49,231	41,315	89,401
Net income	32,195	31,803	26,664	57,976
Comprehensive income, net of tax:
Currency translation adjustments	2,703	(11,079)	(3,121)	(11,484)
Total other comprehensive (loss) income	2,703	(11,079)	(3,121)	(11,484)
Comprehensive income	34,898	20,724	23,543	46,492
Prestige Brands Holdings, Inc.
Revenues
Net sales	0	0	0	0
Other revenues	0	0	0	0
Cost of Sales	0	0	0	0
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	0	0	0	0
Gross profit	0	0	0	0
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	1,801	1,199	3,738	2,514
Depreciation and amortization	832	1,030	1,752	2,019
(Gain) loss on sale of assets
Total operating expenses	2,633	2,229	5,490	4,533
Operating income (loss)	(2,633)	(2,229)	(5,490)	(4,533)
Other (income) expense
Interest income	(12,077)	(12,161)	(24,044)	(24,210)
Interest expense	8,502	8,964	16,942	17,454
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	(32,028)	(31,441)	(26,290)	(56,747)
Total other expense	(35,603)	(34,638)	(33,392)	(63,503)
Provision for income taxes	775	606	1,238	994
Income before income taxes	32,970	32,409	27,902	58,970
Net income	32,195	31,803	26,664	57,976
Comprehensive income, net of tax:
Currency translation adjustments	2,703	(11,079)	(3,121)	(11,484)
Total other comprehensive (loss) income	2,703	(11,079)	(3,121)	(11,484)
Comprehensive income	34,898	20,724	23,543	46,492
Prestige Brands, Inc., the issuer
Revenues
Net sales	26,013	27,957	53,972	55,840
Other revenues	72	79	147	175
Cost of Sales	26,085	28,036	54,119	56,015
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	11,066	10,868	23,152	21,309
Gross profit	15,019	17,168	30,967	34,706
Operating Expenses
Advertising and promotion	3,751	3,204	8,496	5,721
General and administrative	1,762	1,300	3,950	3,855
Depreciation and amortization	151	147	302	293
(Gain) loss on sale of assets	0		0
Total operating expenses	5,664	4,651	12,748	9,869
Operating income (loss)	9,355	12,517	18,219	24,837
Other (income) expense
Interest income	(21,459)	(21,607)	(42,721)	(43,015)
Interest expense	20,882	20,303	42,056	42,211
Loss on extinguishment of debt				451
Equity in (income) loss of subsidiaries	(27,020)	(19,746)	(13,761)	(36,701)
Total other expense	(27,597)	(21,050)	(14,426)	(37,054)
Provision for income taxes	3,526	4,892	6,704	8,917
Income before income taxes	36,952	33,567	32,645	61,891
Net income	33,426	28,675	25,941	52,974
Comprehensive income, net of tax:
Currency translation adjustments	2,703	(11,079)	(3,121)	(11,484)
Total other comprehensive (loss) income	2,703	(11,079)	(3,121)	(11,484)
Comprehensive income	36,129	17,596	22,820	41,490
Combined Subsidiary Guarantors
Revenues
Net sales	171,791	164,772	339,996	317,296
Other revenues	33	798	834	1,617
Cost of Sales	171,824	165,570	340,830	318,913
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	74,380	72,120	145,842	138,498
Gross profit	97,444	93,450	194,988	180,415
Operating Expenses
Advertising and promotion	21,619	21,933	42,423	43,161
General and administrative	13,302	12,912	27,616	24,863
Depreciation and amortization	4,917	4,447	10,550	8,892
(Gain) loss on sale of assets	(496)		54,957
Total operating expenses	39,342	39,292	135,546	76,916
Operating income (loss)	58,102	54,158	59,442	103,499
Other (income) expense
Interest income	(1,292)	(1,169)	(2,566)	(2,389)
Interest expense	25,138	25,294	50,039	50,349
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	(3,601)	(3,385)	(6,677)	(4,835)
Total other expense	20,245	20,740	40,796	43,125
Provision for income taxes	12,363	10,632	4,451	19,661
Income before income taxes	37,857	33,418	18,646	60,374
Net income	25,494	22,786	14,195	40,713
Comprehensive income, net of tax:
Currency translation adjustments	2,703	(11,079)	(3,121)	(11,484)
Total other comprehensive (loss) income	2,703	(11,079)	(3,121)	(11,484)
Comprehensive income	28,197	11,707	11,074	29,229
Combined Non- Guarantor Subsidiaries
Revenues
Net sales	17,358	14,005	31,184	25,613
Other revenues	494	543	980	1,041
Cost of Sales	17,852	14,548	32,164	26,654
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	6,478	4,952	12,478	9,360
Gross profit	11,374	9,596	19,686	17,294
Operating Expenses
Advertising and promotion	3,222	2,756	5,308	5,433
General and administrative	1,930	1,051	2,948	2,819
Depreciation and amortization	116	63	244	203
(Gain) loss on sale of assets	0		0
Total operating expenses	5,268	3,870	8,500	8,455
Operating income (loss)	6,106	5,726	11,186	8,839
Other (income) expense
Interest income	(156)	(126)	(315)	(238)
Interest expense	1,292	1,169	2,566	2,389
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	0	0	0	0
Total other expense	1,136	1,043	2,251	2,151
Provision for income taxes	1,369	1,298	2,258	1,853
Income before income taxes	4,970	4,683	8,935	6,688
Net income	3,601	3,385	6,677	4,835
Comprehensive income, net of tax:
Currency translation adjustments	2,703	(11,079)	(3,121)	(11,484)
Total other comprehensive (loss) income	2,703	(11,079)	(3,121)	(11,484)
Comprehensive income	6,304	(7,694)	3,556	(6,649)
Eliminations
Revenues
Net sales	(145)	(1,472)	(1,365)	(2,200)
Other revenues	(564)	(617)	(1,121)	(1,185)
Cost of Sales	(709)	(2,089)	(2,486)	(3,385)
Cost of Sales
Cost of sales (exclusive of depreciation shown below)	(837)	(1,815)	(2,401)	(3,146)
Gross profit	128	(274)	(85)	(239)
Operating Expenses
Advertising and promotion	0	0	0	0
General and administrative	0	0	0	0
Depreciation and amortization	0	0	0	0
(Gain) loss on sale of assets	0		0
Total operating expenses	0	0	0	0
Operating income (loss)	128	(274)	(85)	(239)
Other (income) expense
Interest income	34,938	35,030	69,543	69,792
Interest expense	(34,938)	(35,030)	(69,543)	(69,792)
Loss on extinguishment of debt				0
Equity in (income) loss of subsidiaries	62,649	54,572	46,728	98,283
Total other expense	62,649	54,572	46,728	98,283
Provision for income taxes	0	0	0	0
Income before income taxes	(62,521)	(54,846)	(46,813)	(98,522)
Net income	(62,521)	(54,846)	(46,813)	(98,522)
Comprehensive income, net of tax:
Currency translation adjustments	(8,109)	33,237	9,363	34,452
Total other comprehensive (loss) income	(8,109)	33,237	9,363	34,452
Comprehensive income	$ (70,630)	$ (21,609)	$ (37,450)	$ (64,070)

Condensed Consolidating Finan83

Condensed Consolidating Financial Statements (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Mar. 31, 2016	Sep. 30, 2015	Mar. 31, 2015
Current assets
Cash and cash equivalents	$ 30,458	$ 27,230	$ 22,152	$ 21,318
Accounts receivable, net	92,869	95,247
Inventories	97,959	91,263
Deferred income tax assets	10,646	10,108
Prepaid expenses and other current assets	11,341	25,165
Assets held for sale	36,400	0
Total current assets	279,673	249,013
Property and equipment, net	13,732	15,540
Goodwill	351,662	360,191
Intangible assets, net	2,181,128	2,322,723
Other long-term assets	4,783	1,324
Intercompany receivables	0	0
Investment in subsidiary	0	0
Total Assets	2,830,978	2,948,791
Current liabilities
Accounts payable	39,041	38,296
Accrued interest payable	8,264	8,664
Other accrued liabilities	67,006	59,724
Total current liabilities	114,311	106,684
Long-term debt
Principal amount	1,502,000	1,652,500
Less unamortized debt costs	(22,337)	(27,191)
Long-term debt, net	1,479,663	1,625,309
Deferred income tax liabilities	459,527	469,622
Other long-term liabilities	2,837	2,840
Intercompany payables	0	0
Total Liabilities	2,056,338	2,204,455
Stockholders' Equity
Common stock	532	530
Additional paid-in capital	453,336	445,182
Treasury stock, at cost	(6,558)	(5,163)
Accumulated other comprehensive (loss) income, net of tax	(26,646)	(23,525)
Retained earnings (accumulated deficit)	353,976	327,312
Total Stockholders' Equity	774,640	744,336
Total Liabilities and Stockholders' Equity	2,830,978	2,948,791
Prestige Brands Holdings, Inc.
Current assets
Cash and cash equivalents	8,168	4,440	10,554	11,387
Accounts receivable, net	0	0
Inventories	0	0
Deferred income tax assets	297	316
Prepaid expenses and other current assets	2,189	15,311
Assets held for sale	0
Total current assets	10,654	20,067
Property and equipment, net	7,963	9,166
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	2,500	0
Intercompany receivables	1,478,481	1,457,011
Investment in subsidiary	1,665,764	1,641,477
Total Assets	3,165,362	3,127,721
Current liabilities
Accounts payable	2,643	2,914
Accrued interest payable	0	0
Other accrued liabilities	11,731	12,285
Total current liabilities	14,374	15,199
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities		0
Intercompany payables	2,376,348	2,368,186
Total Liabilities	2,390,722	2,383,385
Stockholders' Equity
Common stock	532	530
Additional paid-in capital	453,336	445,182
Treasury stock, at cost	(6,558)	(5,163)
Accumulated other comprehensive (loss) income, net of tax	(26,646)	(23,525)
Retained earnings (accumulated deficit)	353,976	327,312
Total Stockholders' Equity	774,640	744,336
Total Liabilities and Stockholders' Equity	3,165,362	3,127,721
Prestige Brands, Inc., the issuer
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	11,677	12,025
Inventories	12,910	9,411
Deferred income tax assets	807	681
Prepaid expenses and other current assets	546	257
Assets held for sale	0
Total current assets	25,940	22,374
Property and equipment, net	314	210
Goodwill	66,007	66,007
Intangible assets, net	191,521	191,789
Other long-term assets	2,283	1,324
Intercompany receivables	2,573,184	2,703,192
Investment in subsidiary	1,538,358	1,527,718
Total Assets	4,397,607	4,512,614
Current liabilities
Accounts payable	9,422	7,643
Accrued interest payable	8,264	8,664
Other accrued liabilities	1,841	1,714
Total current liabilities	19,527	18,021
Long-term debt
Principal amount	1,502,000	1,652,500
Less unamortized debt costs	(22,337)	(27,191)
Long-term debt, net	1,479,663	1,625,309
Deferred income tax liabilities	61,046	60,317
Other long-term liabilities	0	0
Intercompany payables	1,246,668	1,241,084
Total Liabilities	2,806,904	2,944,731
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,280,947	1,280,947
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(26,646)	(23,525)
Retained earnings (accumulated deficit)	336,402	310,461
Total Stockholders' Equity	1,590,703	1,567,883
Total Liabilities and Stockholders' Equity	4,397,607	4,512,614
Combined Subsidiary Guarantors
Current assets
Cash and cash equivalents	292	2,899	0	0
Accounts receivable, net	67,356	74,446
Inventories	75,088	72,296
Deferred income tax assets	8,652	8,293
Prepaid expenses and other current assets	7,926	8,379
Assets held for sale	36,400
Total current assets	195,714	166,313
Property and equipment, net	4,889	5,528
Goodwill	263,183	271,409
Intangible assets, net	1,901,899	2,042,640
Other long-term assets	0	0
Intercompany receivables	1,461,115	1,083,488
Investment in subsidiary	83,983	81,545
Total Assets	3,910,783	3,650,923
Current liabilities
Accounts payable	24,097	24,437
Accrued interest payable	0	0
Other accrued liabilities	47,137	38,734
Total current liabilities	71,234	63,171
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	398,108	408,893
Other long-term liabilities	2,682	2,682
Intercompany payables	1,821,773	1,570,265
Total Liabilities	2,293,797	2,045,011
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	1,359,921	1,359,921
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(26,646)	(23,525)
Retained earnings (accumulated deficit)	283,711	269,516
Total Stockholders' Equity	1,616,986	1,605,912
Total Liabilities and Stockholders' Equity	3,910,783	3,650,923
Combined Non- Guarantor Subsidiaries
Current assets
Cash and cash equivalents	21,998	19,891	11,598	9,931
Accounts receivable, net	13,836	8,776
Inventories	10,578	10,088
Deferred income tax assets	890	818
Prepaid expenses and other current assets	680	1,218
Assets held for sale	0
Total current assets	47,982	40,791
Property and equipment, net	566	636
Goodwill	22,472	22,775
Intangible assets, net	87,708	88,294
Other long-term assets	0	0
Intercompany receivables	12,506	10,738
Investment in subsidiary	0	0
Total Assets	171,234	163,234
Current liabilities
Accounts payable	2,879	3,302
Accrued interest payable	0	0
Other accrued liabilities	6,297	6,991
Total current liabilities	9,176	10,293
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	373	412
Other long-term liabilities	155	158
Intercompany payables	80,497	74,894
Total Liabilities	90,201	85,757
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	78,774	78,774
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	(26,646)	(23,525)
Retained earnings (accumulated deficit)	28,905	22,228
Total Stockholders' Equity	81,033	77,477
Total Liabilities and Stockholders' Equity	171,234	163,234
Eliminations
Current assets
Cash and cash equivalents	0	0	$ 0	$ 0
Accounts receivable, net	0	0
Inventories	(617)	(532)
Deferred income tax assets	0	0
Prepaid expenses and other current assets	0	0
Assets held for sale	0
Total current assets	(617)	(532)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Other long-term assets	0	0
Intercompany receivables	(5,525,286)	(5,254,429)
Investment in subsidiary	(3,288,105)	(3,250,740)
Total Assets	(8,814,008)	(8,505,701)
Current liabilities
Accounts payable	0	0
Accrued interest payable	0	0
Other accrued liabilities	0	0
Total current liabilities	0	0
Long-term debt
Principal amount	0	0
Less unamortized debt costs	0	0
Long-term debt, net	0	0
Deferred income tax liabilities	0	0
Other long-term liabilities	0	0
Intercompany payables	(5,525,286)	(5,254,429)
Total Liabilities	(5,525,286)	(5,254,429)
Stockholders' Equity
Common stock	0	0
Additional paid-in capital	(2,719,642)	(2,719,642)
Treasury stock, at cost	0	0
Accumulated other comprehensive (loss) income, net of tax	79,938	70,575
Retained earnings (accumulated deficit)	(649,018)	(602,205)
Total Stockholders' Equity	(3,288,722)	(3,251,272)
Total Liabilities and Stockholders' Equity	$ (8,814,008)	$ (8,505,701)

Condensed Consolidating Finan84

Condensed Consolidating Financial Statements (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Operating Activities
Net income (loss)	$ 32,195	$ 31,803	$ 26,664	$ 57,976
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			12,848	11,407
Loss (gain) on sales of intangible assets and property and equipment			55,112	(36)
Deferred income taxes			(10,602)	21,985
Amortization of debt origination costs			5,097	4,055
Stock-based compensation costs			3,933	5,034
Loss on extinguishment of debt	0	0	0	451
Equity in income of subsidiaries			0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			356	(3,918)
Inventories			(10,663)	(3,838)
Prepaid expenses and other current assets			10,112	3,436
Accounts payable			820	(4,519)
Accrued liabilities			6,605	(1,443)
Net cash provided by (used in) operating activities			100,282	90,590
Investing Activities
Purchases of property and equipment			(1,404)	(1,683)
Proceeds from sales of intangible assets			52,353	0
Proceeds from the sale of property and equipment			75	344
Net cash provided by (used in) investing activities			51,024	(1,339)
Financing Activities
Term loan repayments			(130,500)	(50,000)
Borrowings under revolving credit agreement			20,000	15,000
Repayments under revolving credit agreement			(40,000)	(55,000)
Payments of debt origination costs			(9)	(4,211)
Proceeds from exercise of stock options			3,423	6,398
Proceeds from restricted stock exercises			0	544
Excess tax benefits from share-based awards			800	1,850
Fair value of shares surrendered as payment of tax withholding			(1,395)	(2,187)
Intercompany activity, net			0	0
Net cash used in financing activities			(147,681)	(87,606)
Effects of exchange rate changes on cash and cash equivalents			(397)	(811)
Increase in cash and cash equivalents			3,228	834
Cash and cash equivalents - beginning of period			27,230	21,318
Cash and cash equivalents - end of period	30,458	22,152	30,458	22,152
Prestige Brands Holdings, Inc.
Operating Activities
Net income (loss)	32,195	31,803	26,664	57,976
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			1,752	2,019
Loss (gain) on sales of intangible assets and property and equipment				0
Deferred income taxes			19	171
Amortization of debt origination costs			0	0
Stock-based compensation costs			3,933	4,993
Loss on extinguishment of debt				0
Equity in income of subsidiaries			(26,290)	(56,747)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			0	0
Inventories			0	0
Prepaid expenses and other current assets			10,622	3,166
Accounts payable			(297)	269
Accrued liabilities			(554)	(2,503)
Net cash provided by (used in) operating activities			15,849	9,344
Investing Activities
Purchases of property and equipment			(395)	(1,107)
Proceeds from sales of intangible assets			0
Proceeds from the sale of property and equipment			0	0
Net cash provided by (used in) investing activities			(395)	(1,107)
Financing Activities
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			3,423	6,398
Proceeds from restricted stock exercises				544
Excess tax benefits from share-based awards			800	1,850
Fair value of shares surrendered as payment of tax withholding			(1,395)	(2,187)
Intercompany activity, net			(14,554)	(15,675)
Net cash used in financing activities			(11,726)	(9,070)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			3,728	(833)
Cash and cash equivalents - beginning of period			4,440	11,387
Cash and cash equivalents - end of period	8,168	10,554	8,168	10,554
Prestige Brands, Inc., the issuer
Operating Activities
Net income (loss)	33,426	28,675	25,941	52,974
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			302	293
Loss (gain) on sales of intangible assets and property and equipment			0	0
Deferred income taxes			603	254
Amortization of debt origination costs			5,097	4,055
Stock-based compensation costs			0	0
Loss on extinguishment of debt				451
Equity in income of subsidiaries			(13,761)	(36,701)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			348	1,729
Inventories			(3,499)	(1,017)
Prepaid expenses and other current assets			(289)	(402)
Accounts payable			1,779	624
Accrued liabilities			(273)	(1,094)
Net cash provided by (used in) operating activities			16,248	21,166
Investing Activities
Purchases of property and equipment			(138)	(93)
Proceeds from sales of intangible assets			0
Proceeds from the sale of property and equipment			0	0
Net cash provided by (used in) investing activities			(138)	(93)
Financing Activities
Term loan repayments			(130,500)	(50,000)
Borrowings under revolving credit agreement			20,000	15,000
Repayments under revolving credit agreement			(40,000)	(55,000)
Payments of debt origination costs			(9)	(4,211)
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises				0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			134,399	73,138
Net cash used in financing activities			(16,110)	(21,073)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			0	0
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	0	0	0	0
Combined Subsidiary Guarantors
Operating Activities
Net income (loss)	25,494	22,786	14,195	40,713
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			10,550	8,892
Loss (gain) on sales of intangible assets and property and equipment			55,112	0
Deferred income taxes			(11,144)	21,506
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	0
Loss on extinguishment of debt				0
Equity in income of subsidiaries			(6,677)	(4,835)
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			7,090	(3,550)
Inventories			(6,596)	(2,177)
Prepaid expenses and other current assets			(735)	660
Accounts payable			(164)	(3,343)
Accrued liabilities			8,284	1,012
Net cash provided by (used in) operating activities			69,915	58,878
Investing Activities
Purchases of property and equipment			(785)	(103)
Proceeds from sales of intangible assets			52,353
Proceeds from the sale of property and equipment			75	0
Net cash provided by (used in) investing activities			51,643	(103)
Financing Activities
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises				0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			(124,165)	(58,775)
Net cash used in financing activities			(124,165)	(58,775)
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			(2,607)	0
Cash and cash equivalents - beginning of period			2,899	0
Cash and cash equivalents - end of period	292	0	292	0
Combined Non- Guarantor Subsidiaries
Operating Activities
Net income (loss)	3,601	3,385	6,677	4,835
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			244	203
Loss (gain) on sales of intangible assets and property and equipment			0	(36)
Deferred income taxes			(80)	54
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	41
Loss on extinguishment of debt				0
Equity in income of subsidiaries			0	0
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			(7,082)	(2,097)
Inventories			(653)	(883)
Prepaid expenses and other current assets			514	12
Accounts payable			(498)	(2,069)
Accrued liabilities			(852)	1,142
Net cash provided by (used in) operating activities			(1,730)	1,202
Investing Activities
Purchases of property and equipment			(86)	(380)
Proceeds from sales of intangible assets			0
Proceeds from the sale of property and equipment			0	344
Net cash provided by (used in) investing activities			(86)	(36)
Financing Activities
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises				0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			4,320	1,312
Net cash used in financing activities			4,320	1,312
Effects of exchange rate changes on cash and cash equivalents			(397)	(811)
Increase in cash and cash equivalents			2,107	1,667
Cash and cash equivalents - beginning of period			19,891	9,931
Cash and cash equivalents - end of period	21,998	11,598	21,998	11,598
Eliminations
Operating Activities
Net income (loss)	(62,521)	(54,846)	(46,813)	(98,522)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization			0	0
Loss (gain) on sales of intangible assets and property and equipment			0	0
Deferred income taxes			0	0
Amortization of debt origination costs			0	0
Stock-based compensation costs			0	0
Loss on extinguishment of debt				0
Equity in income of subsidiaries			46,728	98,283
Changes in operating assets and liabilities, net of effects from acquisitions
Accounts receivable			0	0
Inventories			85	239
Prepaid expenses and other current assets			0	0
Accounts payable			0	0
Accrued liabilities			0	0
Net cash provided by (used in) operating activities			0	0
Investing Activities
Purchases of property and equipment			0	0
Proceeds from sales of intangible assets			0
Proceeds from the sale of property and equipment			0	0
Net cash provided by (used in) investing activities			0	0
Financing Activities
Term loan repayments			0	0
Borrowings under revolving credit agreement			0	0
Repayments under revolving credit agreement			0	0
Payments of debt origination costs			0	0
Proceeds from exercise of stock options			0	0
Proceeds from restricted stock exercises				0
Excess tax benefits from share-based awards			0	0
Fair value of shares surrendered as payment of tax withholding			0	0
Intercompany activity, net			0	0
Net cash used in financing activities			0	0
Effects of exchange rate changes on cash and cash equivalents			0	0
Increase in cash and cash equivalents			0	0
Cash and cash equivalents - beginning of period			0	0
Cash and cash equivalents - end of period	$ 0	$ 0	$ 0	$ 0